var title_f36_14_37088="ICE mitral stenosis 1";
var content_f36_14_37088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    ICE mitral stenosis 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 180px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAC0AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Ur3HRPA/gLTvhro3iXxleajE2oSmFRbRF8MFDdmHFeHV9GN4bbxv8B/Cml6XrGiW15aXTTSpfXywkKYwvTk5zQByGs/DTS7HxR4TutLvbrWvCHiFz9nktbdvtAKnDxbM5LA+/r6Vylv4B1/Xte1m28J6HqV7bWNy8RJh2mMBiAr5OA2B0zmvZdN1LR/Deu/CfwXDrNhfz6Nfy3eoXsEoNvE8jEhA54OMnJ+lWfD1ppc2neJdSi1CHU5R4kuJptPudeNjaWsYc7bkqpBkJGOQee2cUAeBaX4H8T6prl1o1hoWoTapa/8AHxbiEhof9/P3fxrofA3wn8QeIviCnhXULW50i4SMz3T3EJzDEP4sd8nABzjJr3nUtYFx8VfH0Gl3Hh3VbHU7WyZtNur77Ob9VjAzDOp2qVOcgn0+tU7O90PR/j74Llj1uaF30+WG7s7nVftkVg2xvLhExJGM/wAOeuD3oA+eoPh94qvPEd9olhoGoz6hZkedCsJzEDypfsuRgjJ5rd+GPw7l1j4oQ+FfFdrd6bIYZpJI5IyjjbGWHHHBx1r0Gy06/uvh14k8E2Or2Nr4yTWFvblX1FF+3WxjAVVm3YbacZXPGK6nQdb062+Kfw803UNasbzVtG0S5ttTvxcBo97RnZGZScMV5Gc96APnTQ/AnibxHFeXHh7Q7/ULW2dkeWGIsuR2B7n2GTXNTRvDK8UyNHKjFWRxgqR1BHY19TeBryw1r4deDYNHWwlu9Fu52vVm1s6f9lkMu5Z2UD96pHPfHQd8eFfGDWrfX/iBqt/ax2Kh5WDyWTs8UzbjmRSwBOfXFAHF0UUUAafhzS31rWILCPdvlDlQi5JKqWwB74x+NdRb2/gjT7mSx8QQa+byCQxS/Y3i2gjgj5scg5HpxXIaTqFxpOpW1/ZOEubdxJGxGRke3eun8S/EbXfENnJa3gsIYZG3OLW1WIt9SOa4q9OtOquX4fWzv9zujeEoKDT3KfxF0zStG8T3On6GZntYML5ksodmbAJBwABg5HHpWZpGh3mqKZIEC24cI00h2qD6e5xzxWtplk/iTU7i91aVYEYmUn7gck5wM9q3VurR2kihkXybcfKYxtVc8dK6KEJQpxjN3aWrM6jTk3HYzLbw5paXDwXE1xO6qTuhICg/ka6XRvh/ot7FuuJNQi91w349OnFL4TvLK2ZLi52b0OfKztyO3Qd85rt4fFOmz3scLJ9nt1Xe+wYBOOOnp+takHJXXws05mQafcXMueCpcbifYYrC1z4ZXNvaPLp7vLOrY8hxgsPY+v1r1WUqGW90q6DuvylYOMDqScdeD+lN1CS/vNGupre+McaqS0OP3jEEDI7980AfNE0bwyvFKjJIhKsrDBBHamV7P4g0Ky8R2UUcsqw6soB84RAb+P4+56dc8V5BfWdxYXL295C8UynBVhj8R6j3oAr0UUUAFFFFABRRRQAUUUUAFFFFADtzf3j+dG5vU/nTadGA0iqzBQSAWPb3oA9d0X4JX97ZaUNR8T6FpWs6tCs9jpd1MRPKjfczgcbu3X068V5hrel32iareabqUTw3dnM0Ey5yFdTgjNfT9lY+JHt/C2keJvBOn+O9GktYBZa7YBo5YITjAMw5BUc87frmsLTfDdhf+JPiX8K9MuluRM632lzztuZLiPaXQv3OCVJ/2DQB84hZSVAD5b7o55+lX9F0jUdZ1yz0iwhd9Qu5VhiiY7csxwM56V9MaVrcSfHHVbHRNDl1XTfDejf2TC1j5X2m2EeA80SP99925eMnpV3VTqNv8QPhf4iTWLieO8v2sF/tPTEtNQMbEBxLwN644B2jGeOuaAPlrX9JvND16+0i8+a7tJ3t5PLJILKSDj1GRVjwloN14k8VaboMMq29zfTrArzZwhPcgc19Kyy+IH174sarb2r3HjixZItGWW1XzY7Hz3DSQpt+fA/iwTwOTnmC1F7eX3wf1XxjbLB41n1dkkaSIRTzWoPyvKoA5zjBI7n3oA+a9d0i50jxDqOkMxuJ7KeSB2iBIYoxBI744rM3N/eP519caIBp/h7xjqXh+XVLfXJPFdzBeXGk6bHe3SRhj5aFGI2xk9/U49a8Y/aLTTV8fzNY6ZcaZeuitewSpGn7wonzBUZgM8kjPegDy7c394/nRub+8fzptFAHpXhrw5J/widhr9noh1x2lMMlqqNKSwZs5UA7V2hffLCtPUdQ0t/Cmux3ngiw0TWbVoY4iYnMmXLE7lfgAKh5xnJrzvSfE+uaPaPa6Vq9/Z20jb3ignZFY+pANRW8+oajLOjXTkTMJJ3lbgkZAZj3PJ/OvMeCqSnKU5dbqza0vezW39dDqVeCSSW3ku25StYLi6mEVujyOey810enaDJjy7qI5ZsFxyV9h2H41o2cNhbQxR2khUnHmOpyxPv6Cuy8PT6TZlGiuEKlidjruYkf0zXpnKc23hSQmRLbT1dSoZXKbmCnjdjpjIrds/DMdtc26z6FYTK33gVLFsHtjp+Ndu3jHSYViXG2cqEk2DBbvwe30rStW0O+WJ7JzBcSDcpcZ9O4+tAHKf8ACN6JeWc6x6Hp8blCAsMZLhvY5yDXlvibwXf2BmubCGaW0U5ZOS8XOOR3Hv8An619EW9pdRXch8uG7t3HzPAu44HcEdO9LFNpFjqH2prZ8plPKyQVyOTx60AfI7F1JDFgRwQe1Jub+8fzr0f4leFg2rz3miWSxrK7ubeDkBexAHT6flXm9AC7m/vH86Nzf3j+dNooAdub+8fzo3N/eP502igB25v7x/Ojc394/nTaKAHbm/vH86Nzf3j+dNooAdub+8fzoptFABUqXEyLtSaRV9AxFRUUAODsH3hmD5zuzzT0uJkWRUmkVZOHAYgP9fWoqKAJkuJ45VlSaRZV6OrEEfjSNPK0/nNK5mzu3ljuz65qKigCcXdyLg3AuJhOefMDnd+fWmebIJDJ5j+YeS27k/jUdFAE0NzPAHEE0sYcYbYxG4ehx1qGiigAooooAK7Xw/4SY2UWoaggJkG6G2cFdw7Mx9OvA9qwtIgigaK5uGXJcBBn7vua9Q0qaNTbiW4lmX729X4z/dJPegDzrVYJ5LsqrbULEbSPlA7cegqW2gaGeWJmgIXpvGNy+vFex6P4Q0PxDbuVK298y7yS5wCTjoOK5/Ufh7rGnSSpbhbpCNqMgyRg9B+lAHH+WhmS4VeSucluePXsajvWk2tsLAEkbQcHtnnr19KvSaZfWysbm3uSoQ5Ug5wOorORysSBIWIIOSRkgn1oA2dM1C5srgMjGNlwAOn+TXpGheJLS4ja3vR/pBbCyAZGevJry23t5baB42jXeASMncM9afBqTQRM8cnk5fkAcgH0oA9H1XR7sX8kyCTbJhmcyZAz2HtXJ+IbCHXQtnd20olg3JHMnzMv+I9q0tE8VLGr2tyxIOJMyfMGHOcAfyrfubgX+mi5sEjjfYd0o+8fTA7daAPANf0a70K/NpfJh8BlYZwwPesyvaNT0y4vdLaLXE3QOhMczAAq3Yj05HTvXlGr6TPpszh/nhyNko6MD0/lQNK+xnUUUUCCiiigAooooAKKKKACiiigDa03xV4g0uwax03XNUtLNs5ggupETnr8oOK6/wCEXjbQfA8mo6ze6beXvihEYaZMHHkRsylWMg3Anr79682ooAuwarqFvqh1K2vbiDUC5k+0RSFJNx5J3DkE5NTarr+satfx3uqarfXl5Fjy557h3dMHI2sTkc+lZlFAGzN4o1+bVo9Ul1vU31KJQiXTXTmVFHYPnIHtUN1r2r3erJql1ql/NqaEMt29w7SqR0w5ORj61mUUAa2m+JNb0u9uLzTdY1G0u7jJmmguXR5c8ncQcnqetZ1zPLczyT3Msk00jFnkkYszE9SSeSaiooAKKKt6fZyXkwWNGYAjdt9KAHabZG6lJfcsKgksB1wOg960BNC8CxR/u4YyOMZZzXUz6RBbaNP5iTo4GUUAFG9hXMGQOEYRBlXpxgD2oAlKiMZEUjszb3LqF28ds1p27TAmdomywAVgoGFNVLYlJELxqPNP/AcnsfyraM0iRgzeW7qM7c8YA/QUAMkYyAtgPGcN97OOatRancQTxukkcKxgKu3kkehqppyK8bTxbHZ+FUA7ceg74qOOOTyZZcFQC2UKkFTzQB1ej+NL+zuylrI0cm0k7WyATnGR0Oa7jS/GFnfWAfUYYTc7AWZTtJ7fdFeMKAYHlcMjZ4Vm6D6Cke7eOGEhD5SHCyAE8/54oA9+mntryIPptyJ4vl3KI1DAEZzj1rzf4k/DtJ83emxql4Yy+2PG2Yg9DwAG/nWT4f8AEVxaPJi2d5cguQ38PXPtXp2naxDqFsvn+W8rcLFC2QM8ZJ9RQB8uTwyQTPFPG8UqHDI6lWU+hBqOvfvG3w4XXEaa3nWLUwP3byEBJR/dY9j6GvDtX0650nUrixvYzHcQOUYEfqPUHqDQO3UpUUUUCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAoop8cbSNtQZP8vegBFVnOFBJ9qTpkEV0kdpZ6dZrJLOGmkUEgVgXEvmNjAAByMUAJAC0irkA54z0zW1aLdSBUjLI4PJiHQj9Ko2NnFOUw7E9Ttx8tdXYRSwu0kOSjLjc5Bz+AoArWeo33mRkG4cq2C3mFRnPGR3FdVpPifWViLJcTDZknfzz6jFYSX0xuGi+zqHU8M2QCK0Zf3SyRiRYsjecgZX1GO9AHZWnjA3cMcOr20FxE44kB2nnsKwda0C2upftGjud0jAm338qvrnvWD5DLcK6qzgrjpgdf51rpd3dnDE1tBKqAgq2Nwz9CP8aAMKYtay+ROZVUsWUMuC2arag6R2xZYv3igZJXkH616Reafa+I4pZJF23yRjeEyc5H8+vSuB1jSDBdtEh+4gTYRjHNAGbaNLFFDcxsAWBAZl/+vWzoesLb3CpMJXhyN2w4BHpXPzLvIiSPc6cHL8AiqZBe7BYmJgQsZHQ+/NAHtmrxW+pafCLYvIg+ZV83dtwc4NcBewxzXrwXio8TcCME9vf0qfwpriW18La7GUbiSQEYAPtXS67YWWoQebY3MZV8fO2cgD2oA8b1HTZYJZ3hhl+zI5AZhyB/nvWbXqcXliPytQeRbUYxIsefN+lct4s8LTaaVurW2nW0dd5WQgunqcDt0/rQBytFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRSjg0AGMHmuv8B6ZdXl4sli6o24KSwOM+lcioLkAcnsK9L+Hchs8x7lcySLtUHYQfrQBoeOg+kRx2+TtBBfP3R1rhlu1kuTE7ERvypVRtJ69a9v8ZadHq3h24S7hj+2QgOm7rJ9SOteN3QEKJutcbOAnC+1AEkR8wDbDGxH8RbGD7DvVpniedPMPzEYPQDHtiqdhCArOj/MRySSQB6CrDNLsDrGFGdqkDk+tAF77WIogEidxxtUDG7PT/Gqzs1xMLeICJB8ryM5x/8AXqM3I8tY2BCgjDAHcKYkvmE7fmUZCkA5YE96AOv1bwVc6X4O0rxA00fk3k/lIhc7gQM5bP8ASqi+FrmDwK3itZo722+2mzngiHzQv1DHtgjHPvXoXibw/rGt/ArwnBolle6nNFeM8gtoWkKqYgMkLziqfwt0+/Fxrvw/8SWl1Yvr1gXtY7uBods8eTG+CAcHa3PfbigDipPDd1Y+Bk8VC+txbX92bWOKUfvHIUk7fYEEH3rM0XWWsYQSzIVOVZerY7E+nvXbfGyeO11DRfB2nSoLXw1ZpDIF5DXDgNIfr0/HNeXiQNJjYEgXOcAsCccjPagD0TSfiI8lrFC7Ruu7oDyc/XnFaGrf2P4ysEstbhjsXjy8V2oAmB+uPmXplfp0615IoiiJuI06EbQDgZ7fStbTri9uAxmkJAxtBbAUd+etAHN+J/Dl94du1ivUDQyZMM6cpKo7j07cHkZrFr168uJfE0K6XeWyuFT90wXLKem5fT+tefeK/DGoeGb4W9+gKsAySpkowPv2PtQBhUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVt6H4fn1JGuJSYLNefNZfv+y+vfmgCHw/od1rd15duAsSEeZKeiA/zPB4rq7iyHh53tLaHzzIAYyerk+prV8Nz2mnWRVDCke7gK3J46n3qt4g1C2uL+FkmVSmMnPagDlNQM11cOtzDHGqeh6GqMFsbneojjGzsDy30NbXiDUIWZUt03nPVaoWFuqzGVHO0rkq4wQfSgC1o0DI3lMhCZ4EqDOfqK27q3jgt4fIYRyF9wIH3TzVazeSdlaS6VdnK5BBPtz1qzI5+ZmKk+qMM4+lAFmNhFK01zcbg/CqRjFWboRxQyyRxTHIyS3P5e1ULpw8dvCsUco5OXBG49uelXIpWOVLeWh4YH5gv50AacMP2zT1uXlG08cjtn0rP822jRktznDlWZS2Mj2qwWBCRmSJos5+XPX+VQtPZ228KJgzMctG2Af+A5oA6TSmnj2vbXUqFRywXg8etY3ivygo3yySXMrAg5xn24rp9O1XTrTRQm1nkc8Z5wce/auJvpTNdSyOEWLPPbH0oA5+4jUTxFc5bILNyV+pqsLRXCyFiypkxNjOPqe9aEyM0pkSRRHjCrjcB71nw28jysrSThs/3eD7n2oA73wroGn3nwZ8darcWEE2sWU1l5E+csgeUBsH3GR0q38E7fTfEU/iLw7PBH/a93YNLp05ySk0YyUA9COv0q38MdV8MWnw98V+HPF2syaUmpS2zRz21s8x2xtuP3QR1AHPrWW7eEvA2v6Fr3gfxJc6xcQ3PnXC3Fq0O1BjgZXncCwoA7fwpHpSfDTUPEOsWYnkmuV0/TlkXG0ry7qvbuOehFcvqtsdW1q2kR1jhQYEQ5LDvk+lV/jt8QtF8RajpVj4IYtoVjHJNtCPEDNK5eQ7SAc5/rXFaJ4kuLRsROCrHl2HX2BPNACeONAtob+RdOiRLpmBMEfAxj+Edq4YggkEYI4Ne226Wd9Zrexsv2xuPMYDA/A1y3ijQLK/RG0xdl+uWnlZsJL+HY+/f9aLDbbPOqKkmikglaOZGSRTgqwwRUdAgooooAKKKKACiiigAooooAKKKXGMZ6UAT+XGiIxfJJ5GOlRvtDkryKfCQODGHB7Hjn61c8uLyR+7XrllLcg+goApR7mYeWmGHORXceHbS9kg3C4Ec6dyvPsK5iG0DyRmFJFJ5Bb5cewruvBK7SXd2lUsAS6g4NAHc6ZrMsGnQi6Y3EwbY5K54J9PWjXvDVprW65gljt52w375Ao/HFOvfChu9Rt7lLtTKRgQRHYp9yPWtzTbO+soXjdnbLchwGCY9KAPDtZt5tPnFpJDIMHblCQG/wBr2FQzyQxOIEik8pwBksTg9a9z1nTdO1nTt32gLPGCShjHJx0yeleT6jp620jqsy7mJ4Zfu/SgChZO0hZlnZVC4ztzn86jEWJZXVnwDktEnJ+vbFLDpmZGaA7pMZye34VNaecACINsvA2cj8fSgDpPDvxM8YaHpkWnaRrMkEAB8uJbeJgn1ypPas7VfHniW412x1/UdQabVrUKkd0Yk+UKxIG0KBwSeuetZEqIl2vlybtg+bbkY/LvUUrQz3rCWORo1HTdj/JoAn1LUrjUtWury5d5by8Zp55QoAdickkgd/aoLlGeRAisARxtGePxqYjvCjJGSDxyFFaq6ddSQko0auvzBsAcY9+lAHJRRyyeYsAxEkmcyj7x966DTNRFs+S0EcmAG4Bz+HakGmv9nkeSA+a5IjK4GT9O9Y8tkllDJLdW5TB27m5Lk0AexeDDFfv5kLIm0gtIrd63vFkdo0BtruG2u7WTG5XG4/l6+leLaPf6raqog3w2+0blUbePWtqz1dbk+Y0+D90JuPHuc0DTad0cf4/8NLomotNZP5lhMd6D+KLPO044+lclXt8c0K2EkckSTmU5d5sFcZz0rzXWNDSZ57rREZ7dCS8R6p349R7dfrQDd3dnNUUUUCCiiigAooooAKKKKACiirUVqxiMmMkdB2/GgBbG3WV8zZ2dgONx9M11R1Seb/RYp0EUQC7FXge1c+hKxo8reYE5x0FRJfNsfy0AnY53KO1AGumlxWs4kecnB3HHAHsazriaGS6LqhkPQsp4qmL2fGGfcD1B716p428N6Zpnwj8CazpVokWo6gZ/tLbsmULtx+WaAOGkiWPTVntYVkYkFg4+ZPetGGNHhjeRzGMA/Ngg/Q/0Navwq8OyeLfGulaRK7Rxyyb7j/ZhT5n57cAge5Fdn8YtA0rR9Z03U/DshTw3q1sJbQKmVDodrof0P4n0oA4MqSimOOJ8DptqzbmCNAfs6LMw3ZPP4VBbzq21zEsBVsEqc/jVx7q5s9xUJNCx3B9oOM+1AEEl/vu440McKgHIOCre3PSkS4s42IETTlTkxg8c+xqKcJeKr+UTgliGXgmpbNFVgXU+X2Dg4+lAEm6OBvLZGVG5AI6H0p9quzUNswLQkHBUbTmrTG5dwzOkcS9DtzmpIYt++Z7tWVedq9R+lAG74Tezmnu47xwGG3a7jaQMHjHeszxZaQC7kEZMkLY4RcfqKwdQ1EWDhmWRe5KqGOPpUbeKreW0mi8q4YHoz4GPwBoAjNvIrsbYyKV+8QCdo7dutQT6ZHBA84uGd8Flz3P0q5pGrS28rJGV2kZIDc/l1p91eJPdos0YeQ/xDqPoKAMYJMtsrzzfvXH3MDOKzFaQ3BiZ9hZjjPPHrXQXsNw9xHFDbHGPmJ5/WqeoWvlMjMiySrwAo5FAGfZIqX/ky/MpwPkXHfpWpPo0rOzQEQQ4wCRvP4HtVBFk+WW5kKs+VREj5H1rs/C98s9s1osfKZG1vmPTv2/CgDndOaewJWN2mjQY3DjNa1nfPNyoxGORgcsc1esVtk1CR9SDAE/cx0/AcV1umw2HmfabaKGNNuA8xz/3yvY0AebeIdClvIhPcM6TclSy9e+PeuFlgliLCSNlK4ByOmelev8Aie8YXYE29/MyqnA4HsO1c1rOnrfW/lwLiNRlpd3fnAx0PX9aBq3U4CirN7aS2kpSVeOzDoarUCCiiigAooooAKKK7D4QWlvffE7wza3kSzW8t7GkkbdGGelAHH0vPSus+LVrBY/E7xVa2kaxW8OpTpGi9FUOcCvWfgH4U8Of8IfJe+MFAk8UXh0XSyTgowRsyDn+/hc+oHrQB8+hyIyoxg9T3qW2YM6hlx6sOpHpVvXdNl0fV7/Tb9GjvrOd4JVxxuU4P8qztpyeMEdjQBu6dJbyTBCxbHqMEHsa9N0HS51hEzSxSRYHMDAlf95ev5V5hpQniaKRVLcYIZOn0I613Hhm6vozIlzHCu7GFVgCRQB7FoFzJLZqm2N1T+Mpkj8a6J4rd7VXyySkAAqx+Y+4rzrw3qQtplS5WaO2kJyhPT8fSu2tda0p5lt0imKxqCWDgrj6GgCpqazeQqDSzM5B3ELkn9a8v8X2kn2keVZ3dtMVO1WgbDHtnivoLSJgY2kWCTZn5ZI2D8f0+lMnku7l1ee0fyU+5NFJuJ9iO1AHy1Hb6iGUSJNHKBl/k2Y/3c9qe8H2hWMkd0zqPmYtyPqO9fSmp6xcLIr27QqEXaTMikqfxFeb+L9YuZZGH20NNkkJCu0D3oA8zj0ycKxgAULyCwIx+lVoYbiUE3DxworHa2DnPTNbes6nes5fe8jEDB4BX15rAm+2Ts+xnVzyGkIkPvgUAbtjY2l7ZIskjySICdsbbc+9O+ySqMPC8YGMMuBkVkwXE9oVMLiOXA8wcc/hWqzme2lkWQSNjB8xsH6ACgCS1u0tJZFnMghXoAm7PvmqqPHqM2+4eKCFWLB5ACAPbrzVGUStHHC4cuowoDBuPx4/GpNN0mVlMakvIe2RgfU0AbsESMjNbTtLahflUDLM3uSOBiqel+Hri5+0NNGuW6jAGBipIUOmo4Eiz3OMER5Kp/8AX+lVjPL5TyNJIvHEW8gE+4HWgBgJtpXtY1ZYrc7SGXIJ9jVG3u/NExjjD3G4uOmFPqTUd1Ld3EiKrkIvICjIzVW6huQqLPIY1PVM9aAM7X/D/wAhu9NTMYH7xAc8+ormZY2ileN8b1ODggj8xXqWir5yxR3CeSobgAcEe1M8Y+FbHUQ1xpLKl/wDGmAkn+B9+n86B6W8zyyipbq3ltbiSC4jaOaM7WRhgg0UCIqKKKAClpKWgC3p9t51wVfGF6jvWpctBaRGIqPnHRaybS6MDEkbuODnpSRXH7/zJ8yH1JoAdczo8YjjQqAarjchDDj0NSSurSF4sqT1BqxY+XvZbhdwx0I6fSgCO2xM7eagPfIHNfSEGh+FPG3wj8GaRqPj3R9EvdLErvHM6M5LkcFS6lcY/WvnyzEYlZYgEYnGCdysKtf2cFkQvbAHOchuPyoA+g/CEHhr4UWHiK/svEGj+KNQkiitLVQ6qHRzmXKhm4xgZB7ds0l74k0nx58NNT0y4stH0W70idLnT7e2fYsgbIdQpPXknj2rxSykilgWJowka8fOo/8A11IbW1mlAtY4ww5JRmH9aAGQmNZCk6/Pnjiru6PcqKQHXorJlT7VE9s8MqO7Hg5wWzn8auQLZyuzsimTuWoAext3dT9m8s+hY4/Cnx2gDtsieIBc5V9oNVPtDXExRRiBQfvHBB+npWhawT3EUdsLSOYuem7OfoTQBUjS4it3kEzSyZ4yc4/PrRbPtVnuYkCseXCrnNdiPBl/FCst7b/Z4F+85k+UCpYNNsbRCfJmunHQKCoP58GgDzbVJJAkx+dlZDtYjIBrl7WOQOWLBN3qpz+Ver+Jb7zrd41sJY2I4wgAX6mvKr6+mSdkZsMvBZQBQB0dqsUcSGRHaU8EkgZqC+uvLmbYkyYHzu7dvRf/AK1ZtjeeVCkjsXZjjqAfxrV1OxN3bgxyRKuOSoJJ/E0AZ8mqXEzoIo5AjHG5z1rY0S+2XMkFx5XzLkORgj8a5mF5IHeOGUybR94jgVYgk8795dTZCnIz8oFAF/XolAVLWT5d3VW2j6e9RWF3NYXVvHahy7sBjP3vqatWtlaSEy3U8jo3zIoGf51Wvh5aSSfNHEB8uOv50Ab2r74P3k20XDrtRYzuKn8O9X7O/mt9OSOBGluOmBgke5rlNI1SARmImWSUnjIyT9D2q3PazRRFldoIHOdqn5nPpQAXQ1TVr0Qx7yS3zMhzxn17V1en6VbWcSy6vdxxwxg7bfOGkPOCR2XP51gWWsXNltjSGO1DYHJ3OauXF5ZHDzxs82RudvmZvYCgCPxEsF3btHFHGlu7bi2MA+m2vO7mNYpmVHDqDwRXoupXIvVSC3iDS4yFfoo9Tjv7VxviO0js5YkWQSSnJkwOAeKAMaiiigAopcUlABXU/C/VbLQviF4f1TVJTDY2l2ks0gQsVUHk4HJ/CuWooA968b2nwc8Q61reuL421hb++lluhCLB9gkYlgvMfTJx1p3iH41r4cttA0L4fw6VfaNpNlEq3F9YFnNx1kdQ2CvODx3zzXgoBABI4PenCPIJBBI7UAeifG/XNB8W+KLbxB4fnLXd/ZwvqNuIWQRXIXD4JHI4HIrhrJTI4KqskgB+Xvj1qBIZUZWIKc9ehFbltZPMibxIkp6TIcAj3xQBsWakQxyLEZCBh1zyPcVdnnFvImVK4/vEcj3pLK5FrZmLzlEvTc3IP40yB57lglx5G3PdCQPxoA63R7wDE/2oCD+JMH8/Suu0qCHUZxPG8ixsvyseAfoa89sNPRiITIFJPyhSSDW3aNq2mXMa2UzxxAcAg4b8DxQB7R4VjWK3LXM7FQNo3DaT7mofEF1qFtZSvp9z5MKKSQZAVA/CuHfxvqMZj+2WgzHwSBj9Kw/FvxLaSyktjauIJF2sz8AZ/CgDK1/xDqUnn5uEuNp/hPX6ZNYH2+6kt/nVtv3jublfpVZW85GlhPlBxkfLuGfcVUkVUByslzIeqw/uwPc0AXWvJn+VY4ZVfj+8340xrV/PEhLhsY2hcAfhWYglM7Kkboo4Hz4z9MD+daFhPA6kSs25c7lQ5/M4oAZclUldJZCqqevBLH+orU026t1QwXeQT0YkDAI7ViXd1ax3GwAyvJnbtXp+dSYDxsizASMAP3QGcehoA6Py9NljKRuwZRy7fMT7VFHC80vkQyNDGnzMzHbuHoBVDQrj7FcrDFDFCmcFiuSa6bUvJuSsjxhwFwMnYKAIWuIZbVrSxABI2lwPmJ/CqM3h6SRCLq4WNV5MaNnp/ePSpdMRbW4AjtowG53KOn0z0+tWtS1i0Cm0hjEjNwWByPyFAFHS7NI5mlkmEiLkRQoOP/1VjT2NzLdyzXEi/Ix2xr0rQkv0tl8mNnQMeRF8p/PrV2y0mQHzEBGedobJ/E0AYRluppFE5EQ6KDnccdMDsPc1cW9mtUVmCJt4znp+NXpdPugDI9s0aMcKSMFj+PJq1No1tFZA3pDTuM+SD/M0Ac3rWnwa9ZqySEXCcicrnd7euKK31014rcMECRjG2NOn/wBaigDxeil7ZoAznkUAJRRSlSACRwelABSUoBIOBwOtKqkjcO1ACAHGa0rOVPKCTAqB0PPFZ7OWAzjI74q4ixyxqVmUSYwd5oA2rYW0cZWSQYc8MD0/KpmjuBbkRypMqnIO7n9K57yCp3LIoK9l5FbmnzRvbH7O6rOP4SvB980AWbEyzKVlOZB7cVYNpJvDrFhO4zhqihigkImZdt4BgtG2Aa0hrBjQx3ESEgc71OfzFAEs9zb2/lIY5PmGBk4IpDlcNGF8oN8xYHJH1qld26zGN7eCcZ5wJMqR7ZqddVaNWgktztHBLDn86ANAXCOvlxuybP4SQePoa0rSRb0IsZVETHzBuT+ArmUjCmaaORm8wYEcv3V/HrV/SQ8ciERxwyA8EHjNAHrGlPZrFHbS6gqmTkLOp2/kRVrUruTT4tm+0KngNGgHH41wGo6/ewWDLON4xwyuAP8AGuai8XTIJF8oyr6SzMV/KgDS8a6mkoMMjybmU8IOPzryu8b9624bkzwehzXQ61qst2p320aRsOVjXhfx7Vy0shYlf4c8AHigDUsmhjsg0kik44TgmtuMs1g0kAJJXkMa5nToVuZNjIDjB3bsV10b2cVk32ggMB1544oA4tZZIZ25Ab3qaGSaWbzP3ZIH3n4Apmp+V9pJg3eWRwWHJqvGxXlc5oA2tNnRbhhdTCVSQSQSo/A4ra1W9GryxWyRxxQDptXC5/ma5J7yV9oVUDDgEKM1oWMFxCTcTo+Rzy1AHUaJ4egE++5uRDbDqUU73+g7CtPVTBEgdYzDbJwjynLv+HaudsPFIUbGTj+6gxn8etP1W5h1CJVc7VHJRQcfn3oAz7nUbb7QBB8zseT71H9tH2tFX5gPTsfeoGmt7CMhIA0jd26irnhnTH1W9jSytt7luXZsBKAN/SbRp42luJBDA3QD7zVgeN7doJrbKbFO7aCfm7da9Sit9P8ADtgFDrPqW3BA5C5ryzxgsk1xbsVkaSRnIB5J6UAczTirAZIIrt9N8JwS6QszMZpGP7wqOYuP1x+FZV/oc2nSxxzI80Eh+WUA4H+eKAOczxR+NbV1ojL+8jP7vup6rWbcWskD4kU7T0bsaAIAvqcUMAO+al8rAO4MPXI6VNHbA7QULBjw6nIoAqknaFJO3rzSxuVdSvJHGDWrZWSMx3qdw/Srk+hmVTJboM55xkD8KAIIrzMQWS1LH1UbsfWtXT7vfCUaEYxw2NuKrWenXCgF4zgHBZM5WtUacwtyBMxkHPPU/lQBlwyvPcyIzJtzwGXOK0Vj1e3k328D3ad/LAwPwqCTSp5CWEmYj1Tv+dXtKY6XKGt5pzg52vwfz/xoANNN3/a8E9xFcQMpz0O3/vnNepW73FxYRs19YFQAcMhDiue0a2j8WFJJ5ora8UlFWbK+46VoX3hTUdKO6a5O0HCmNCyEH3oA6e30aOa2d2ljuHcddwJH5VhDwHC5ddTs3NuxyJPODBfwz9Ky0uPEEZ3WM9vCcdWB+atC20/xpqiqV1G15OCoSgDC8ReFI7JT/Zt/5sIxhIfvL9ea5gm6ifymg56F8bifr0r1WDwJ4xvZFRry2iQ/xtIUz+S1NF4C8QafeIipYzbvvSGRiCfU/LQB5jFYx3COsatJMFJCqdpqkthexF0j06dDnltjOcfUCvWdW0S90vVo5bmOxJ2g4WImtkam/kLG0caDaOEQAUAeInRdSuSFGmPIucE8qQP51c0/wteR79tvJHuOAGOMfUmvSL++v4HWUCJos/djyGqCFtQ1dWlXRriFF4RpJDk/mKAOVsfBmoKVmnvLSCPOeu5xWxb6Fp1oPO1G7nuT1CL938qn+x6tFeBnuLK1PpL8zgfjVbVBazXBW6nE0oHMjNgH6DNAGXrF1a3DiKwiZc8Nzk/TjpVCXTrq2UsYbaKMfxM39BXRRXa2UWLXyst0yOD/AI1Su5JriX97GJHPGVU4/CgDmneKRzHteVhyxgjP8zW7pmqmR0t7WF4o4xl5JWHI9q2bW0jjhjzEeR/q41G4/WqN3bSrfGLyo0iJwCRjP09aANkmG6CvcXaKwPCnkn6Cqt1DbQ3WGV5Zjzz/AJwKoi1gtrtFZpXcDPy8Crd3eRm1KW+EUfxINx/PuaAG3/nMgCrwTwnT86KsQm2gjBbzp5jjcOp/z7UUAeZyeEgzCJZEWAjMUqjO72b3rEfQ3ilNvdRiOUHj39x6/SvWtQ0X+x5mms28y2l5wen5VTnsINUtC0f70p1U8tGaAPLZ/DlwtsZYvnIH3V5z9Kpx2UixsskTlh/CwwQa9FsklsbnybhS8JH3sfoalv7K1uVEkZTfnnpn8R3oA8pSNvnA3AjqMdB701YpOqKSOmRzXeXOnweaBPGYpQflIPB+lVls4451Z4y/PDhcfnQBzMOnTeWXaI5/UfhU0WkzkltqiNscgnIr0LS7S0v0EbrskHQgdR7VrQaKkI4XeoPDRnp7EUAebJo17AVkXyJF/vAc1L9huFClAo3cMduBXqR0ixnKG4tAkgORIvA/EVdGg2iwlZLR5YGGd8fK/SgDzzT9GvGQPDbtJxyUbNbVn4aub4eYkakjqrLgg/jXXWmn21qwFrBNb5HDA5/CtW3WS2JF0kjK3R0yuPqKAPN/+EYvWu1QiWE5+6w3qw/A8V0K+DJWtVVkZg3USDp+NdWHjikVoTCHP3c5yT+NX7bUJ4MrPZM8fUtHIV/TmgDz5fBEiytvRyOwWamvps+nN5as8rHgIzDiuy1HV7eBmeB5I5CTmObLfriuUv8A4miylWN7G1k5++Bz+dAGbc6bdeSZr8BVA5Uc8fjXJ6ne2oLR7dkecZbjP4V28vxJ02Q7pNjg/wDLJmNVdQ8ZabqNqUjsEA65dFYUAeaobVt0USSGNuM7T/8AqrGvEEN26quFB4Brqr6RN7uJoBFg/uohtz+tcreOkkzNGgRfTPNADYmJlyH8s+qitGe48y3Km78wgfxA1mLIQMAL+VaAadoM+WrHHBAC4+tAGezu+AxJ+vFI6lMZI5HY06UsWBkO5u+e1R0AORyo+Xhs9alEk8j8vI/0aoAcHNX7C0N4WZ2CovGB3oAn021eSUGOEdOpGQPqelWgivI8U0rDbyWHGfbiprC9ltwIfLjEan77nJqR3t5ztRUml9C3yj8BQBLp2jW1w4kvpwsWQFQDcWrdM0NmywWA8hOgC/eOfcVm6PZXMId7q5QFuFAABH0rehsUs0WeUNLMThQTjigCwsTLChlJVmGQmNzt7n2qO9s0tZrTdKouir/eAPHGRjt2qxbahb2rFmw9wRwM8D+prmPE2tFri1eeHagZ/mC4IPy0AdFpQhtb1kifyZG6rnh/p2P0rqRZRXUBieCL5uDH/C49R6H2rzaK+kuh5U7Iy4zE4HI/GvQfAVw947WOpJIJyR5UvVGHPBPUHjrQBm3fhU2xaew3bP8AnnIM7fb1rMvtIgkttt1ahec9MoT9R0NeparpF/Yv50EZlVR90nJI/qKr2mnR6hvbTWEV5j95by8KT3GD/SgDwC+0pbdma2lfHTZKM/hmqyiW3G9oI3hPLBWx+hr2/V/C8EsbJcWJt5ed0Z6H6V5nrvh25sVb7MBJbY5VjnFAEWirp07qyYRz1VzgGu40zw/aagvl2crsyYLIMZHtg9a8rtbtbfMF4sLIDgHb0rufCmsvaXqSxzKqLjcoX7woA9HsfCSRAEcZHUjkfn1qC78Eafc3TMJ5Ip2444Gfb0rtfBvinSNRQpcPCJM44PUY9Otat5pum3Ekj2JiMrdg+PrQB5PP4CNuCkivKp5VmPX05FZMnhm5tzhI3Ug/xYfNeuJvtd6TCGWIdELZP61z2oS6dcXBWCBUYcEOcEH2oAzPC1vc26ZMEUmCcoynJrqnuSbcr5DwHvszgVnW2n2wuI5BNJEy848zFa4vY+YpkjmjH/PQDP5igDKub+3hjGI97dCAACas2uqWwUR/ZEjdh1ZwCPwp0tlazcQ2isvXDPn+dZF01raXQ821baBjGMfrQB0aX1uyDyXhMg/uHJ/SrAudRmACSMi46vKqgfrWBpl9FG3m2cLKPdgB+nNLqOuw3MTRPEMHhizN/OgCzf3MsM2b6eGRAOW3F8VZsLCC7InAzEw/gX/GuZLm4QC2ljVR1RPmz+lTwX1zabUhdMkYO5TmgDo30OMBjHJIo65OM/nXK6peLZ3aQxTPMMc4fOPyq3dardLEFu7pIs8heDxVH7bZIpBwpYZLpDlvwzQBlziKS4adjC07DaJGBLAe1UpNGtfO8+4ileTrnditpI1uSwtVncdd8rBc/gKh1iaS3iRDJboRx83JP50AZ91bSTHNrLBCB03gtj6Ve+yDYPsssskuMFgmcn6msOzeQTtcXiSdcKCcA/hWhdT3ot/OX/Q7frgnDH8OtAA9veQI7mVoIgfmdvvsaoyyWjxhhPLJMRgHJODUZka6UG6M8yE/Ipyc+/FPKSQ8WkADkckDJX6+lAGZdvdELGdwDcYPGfw6kVuaTCbi3EbBi6DBSIbf17VDY2N9dOIrWIqGPzzMMsfZSf6V6N4P8KXlpD9ouYxBED8ryHBP0HWgDM0HQbhVXzAtrGeeTuc80V6bomnwQyNMP9Jl6bjzj+lFAHl1hpgvLJlt3zhclG+8v1H9RXDa/Y3/AIeu/PtoyAOWXOD17ev0roPDfieCZIo7svBdYAWbpu9sj8K9CK2Ou2DwanAknG0sV9uue1AHjcGowazCSEFtejocYDD8KiudFSePdLHlz1MbY/KpfGngzVPDs73uhyiaxXDPHnJ98ZrB0/xZHIywXYkinHDbhgZ+tAFbXLFBbBXuZFwfkJ6j2NUNB1AW0jwySsspPCvna3HUHtW9qZFzA0khDoMnd3H+Ncrb2z3Nz5kbLKingrQB2eg3jy6pGGRUXB+ZcH8xXsOl2lnPaK1xAruQP3kJ5/GvEdLhjM8a+d5M2OhrtrR7tYinmSYI+WSFuR+IoA7ptPzKRb/Z5O4WVMN+lWbWBUiIe0jibptV+tYekySQlTdOJnHd+/8A9etV50aQhxKCfunOQKAKlxaJJKXhLqAeVVsg/UVn3AKsFt5MgHBVy2fwNaEllOsjTW0RYNyTEw5/Cs64tI7wsd8kcw67gVI/GgDB1xzJcKy3T5QY2MmP1FYt3r4tBsLsJFHG7PNa2oaRqKyYCvcxsOWJHH41gapp89uNs9veAHv94fgaAMXVdd1C6YKkyGMt9xzwP0om0J3tvORYZSRkqJcH9akuIbzjYhWMf3kBP865/UbLVWc+SGKn0G00AVNSso0JaSzvFCjuvH51izSkEhIwY+ysPu10lvp/iCTEbXk8Kd/Mk4qB/DUiysbyeMsTkuGJJ/IGgDnwGeMnySW6cLgVKulXbYKx5BHXOK6W4j0q2YCTzlP985AFIusaVbY8uSRyOuY9386AOTktpIXIfarD1YVM1rK8ZkbaD1PXJrcutSi1AhbW1ZOcl1jHSpreGwK4vYJy3QHfgH8AaAOcuII0i3AHd6mqdbWvxWsTKtvF5Z+uf61i0AKWJABPAoDEDAJxSUoGSAOtAGppUEM+POYsTnCbuK6mzsbe2GYjHGCOQo+Y/U1y1hA0YDyOypnovOa7XQ9NnvYg24Rx7eM9TQAWOkSvcbrW1LH73mOc4+gq4dPl87EjmQD7zvJkfgBWvObmK2S2tZNoxtZt2KvaDpU02IY0MshPzSnhV9smgDmkUeY0Vsg44Z1GSfy/pWP8RIhZWmj/ALhlVvMJ3nlj8vX86930fSLSxiBkiQyAfMwHGfb1ryb4+3MU8ujJDnEfnDpgD7n+FAHH2Msd2sawDymXp3De3sa9E8I30sU8XlhGlRs7Sdrkew6GvItG85Zd8I3DgMPSu70pL2aeMIgKgjD5wyGgD6X8P6rbalp6W86KXxyjcfy6GqmveC4L1DNYzvbz5znOCPxFef6Fe3aQRxXUUglX7s8bZJHbPrXdaN42iikW01CCRSBgSdVb/CgDjrzUda08nT9dh+2RkYSXAWRR6qe9cf4iEAQh7i4LHGJHQZHsexr3ufTrXXIX+zSIOD+7kX7ufSuG8QeCZ4JzJfWzuqpjzIvmUj3oA+cNW06R792aOOWJm4eP5W/EUkaahaPxHt28qwU5I9xXqWueCDNvl04nOfuFdpFclDbappc8kE0ZYZwEc9KALfhjVommRrm4MUob5WEZx+PcV6poeqySpshuIZz/AHs5P5da8ig8gTq1+htzu6OOD+NbjT2VqyujlY8YDAgn9KAPTbrV5rOcCdo3Dfwk7cfnWNe6nF9oRihiQnlSVYNXMG4kaNXttUglAGfKuC2ce3vW9pE8Gq2Y8uJE2gK25O9AHZWkdo9puxuyDwOCPxrHupDbXBMUysuT+7ZVJH9aTTNPaL5Y5VQg8bG4/KrGoxoIwt1GWI53hRzQBlTajdSHE0MAC9CqgH+dUk1udrgxy2qSxjjdk1pW6RSP5cW1G9XjGD+tTrpNqXzczXMbeix/KaAKTXlu8REsUqL1/dxbqQ+INHt08sW0rsRjE+Rn6DNXtQ0lJrQJbRmSMc5kIA/SqMOlaRasPt08xbH3YYwf1NAGbJe3Dh5LO0kgjbjKKcH9ahs9Rk84RXEKKxJ+aVmGf0rUm0xb+QppFnMEb/ltNKB+lO/4ROK1iL6jdxI5HGWLkfpQBl3TI0m7eCxH3thAX8zVg28VxGp8/wCYDjAI/StqyultrZY7GxhvCBt82RAv480trbPNcfadRkMcw+7sTgCgDmL6G+sbdpmmJtxzgAhm+g4Fc8ZxevvEbR9fmKEsa7zXdFkvixS8lYE8KQc/lWZa+HJlYCVp0A4GOM0AY0Nk5aMRRtKOuXPNT3sEkzxpdTpCx6Fsn+fNdVY+GhHMZHuXRfSST+gq5JpFkriVcyuDxhcZPpQBzGk6FJcS7Yvtc5weUQqtdBpvhqSefyrhSqryIxz+ddRo+m6nPGkds5t4zyQVIwK7HTfD8NkxnmJuJTg5bCqv0oAq+GtJh0yPzJooRLnKl23H8PStKfy9QuVEkTzBT0CkKKsJdW0e4skKv7H+vWsXxD4lFhaOVhkYcABPlH60AaWoajBp8YjQuzAY8qIBVUe5orzCXXJ9Qy12ohj3fJHGx/U9D+FFAHk+jJLZASygPbkY3YLA/Ve31r1LwprSrsH+rVsBXU71P+fQ15l4U1EriK4GRj1xXWwFICTasBG5+YHg59qAPWntrXUosvDHDM2QGj+43sRXmHjz4SW955t3p0fkXrHJ2/ck/D/Cuo8P61JbxBJ08yEnG9eq12Vrqtl9jwWMkLfw9xQB8mxRX2mTPY6tAVXOzZJ8p9OD3rVttMgt2UJFK0b/AHZEXlPrXvHi7wRY+J7NkGZhz8pO148/3T3rhR4Wn0NNhkLwryd4wQPcUAcj/YT3WQypKf4XVtr/AIjtVqPzNHCQypNHzjLggfmK07+NV2vEgIBBzux+Rp0uqo9qsBcSrjBVhyD9aALljekKHNxvj4O9Dnb9a1Yru2uisbqXPZ4ztP8AhXIx2MDHzLWZoyOSGH86swho5RLGwMq8h4zjP4d6AO5gii24jvZYmxyCoyPxH+FRy29sIcPqfmHoQ6gmsOG61G8tgI4hLjqOA386rXOoFSRd2r+YOgbg0AaIs7RcyWs4IX7wO5ahuSJoCouLhQRynDj+WayHljuZQ43wkeuaqX1zHAxbzDvzw3zAH8qAE/sESytjmPqN2Qadcw6bZQEXEcsjY4w7Y/nVT7ddODicxjsSuQayL2wvLkF4rtHPoGA5/GgCC+ltZNxhtZ4067klyw/OsuVFuTt+03sif882fBH44rcsYprONftZlXB+9Fhv0Ga1murIwqSru3q1sQT+NAHEGDw/bKftdlIzjvJcOf0AqubrSSf9B0uFiTwTGWH5tXS6jrFoQc2s2AP4sKPyqqb5buyHkmC3i6b3AGKAOR1P7W4BeKOCM9FRf/rVlx3tyGKxFmxxgAf0FdPcx2sB8ye4imBOPlfANXbQWLqGhVFAAI3kgGgDiJ7S7K+bKjEn8TVMqQSCCCOua9QaSyMW25lBXrsiB/nisLUBE7utnZuydnySf14oA5G3CB8yozL6A4rTtZImf5LdEUHqoyR+Jpi6RMzsZmCZ5+8OPzqw1rFGu3z5JsYO2NePzoA6DS0jlUbFjA/vYMjH+ldBa2lzN+7T7U4PACcfoOlcpom4zh8eQicBpDx+VdnYXtuHCpeXU5HJSFABn3Y0Adjovh3SNOiWXVJCZDgiPP6GuptpRIEj0+OKCE8DaOa5TTYnlTcbSQAnoBuLfia6A309jbNHbQeTnqzHLH8aANWe0lWHM0u0Hkl+p/4D1/OvCfjo9u1zpQt8nBm3MT1+5XbXuqXFxO8UshCbs/LyWNeffFyF/wDiUgLyRKcdT/D1oA4Cxd4plaNijZAB7H2Nd1o+pTF12kxzqQMZGfwHeuP0y2jnYKspjmBBKt0Ndha2kI2uy5weoOCD6g0Aei6JrziFI7iP973GMKfoOxrpEuFmjDKFYd0PDJ9D3rziyCOgKXQLf3ZThvzrah1KW2IUXKBiANrjNAHo2kXjJC2ZRIRwpxsZfxrY0PxBKt55b3aSb+GguDjP0rypvEEsMYbfGuehRsq3+H41VOr3EsyyvBvU8l0fDL+A/pQB9Bz6Zp2qRGSWFbaU4JeJv8iuW1nwTJMhWWKzv4OdufkcD1z61yGi+Ir1kWGKdyAvGH5/EV1mj+KbiF2S9S4dW42soOD7GgDhL34f2MMjeY91CevlyR7h+lYmp6FYwPsNvHLEuPm2spr2G+urO5fdEzMW4KyqQR9DWTf2SSoVNkk8R6NnBH49aAPI7jS9HbDxy3Ubg/dYblFbOnaFIybrS7hkXqNrYJ/Wuq/4RpN7ZtWRW7lgRSxeFrCAhyLu3P8Aet5Pl/I0AZi6lLpo23sCyIvJdo8kfyp41jRrxf3kEJzyQjFW/I1rT6SrxlF1CKZG7XEW7n3INYeo+BdQkYy2kNlNk5xby+W35NQBYtbOCeUfYmmMefuFgNv59a62z06d0VI1Minvt3fyrzG80zxNp43WtrqKKOoWMMfwNXdE8b+ItLhKyx3uM8+ZCAf0FAHqg06O0g3TR3LgfwLF8v54zWLLPapPgrbQgn/lrnP5VzsPxU1cZ8y2eYf3SgX+lQaj8RLS72fa9GVpD3J7/gBQB1txLYsuwXyiTrthiA/WmiMFAWeSWPtvQD9RXnuo+JxKrRw2UduhH8P3h9Oagstb1ID9zJKUxgADJ/lQB3typdtkEMmwdQkbfz6U+3hitWJltPLB6kgEmuX0zV9ZgdmW1uJw5yd4wK6mxudT1JWI0xA44AnBIP5GgC4HtWX/AEa1kkf/AKaHC/kKqSwX4y8iQRA9Oigfhkn863dO0TVryNUuVtrZT18mMjH+frXS2mgNEio5gbA+8y7iaAPNdM0g3U5dBPNk4Yopx9Oa67T9PazZVg0qSaX1ICjPuTXZRxx2kfKRgdtigVnz6jcMxaOEBF6yMcAD60ANE91DCu6GCCT+6rbm/SmXe65jCXMoA67FJLfj6VyniDxe0E7RWzwecMZIGfyrEt/Ed5Kz7t00jHooOB9aAOr1C90/SIWxLFCwUtn7xrzXXvFFo8zMz3F2exPAI+lW9evJfKMl2ImcjAWvPL3UbYXLNcNGW6CKM7j+fagDUn8QzRxmVEYFunAGPxorjtS1aaWUlQEQfd46UUAS6XqFm8phucQTqcMy8c+4rqRNLZw7pB5tuf4uoxXmKTrIFW8QtInSVflf8fWuh8P69NanyQ3mRsfu9j/wE/0oA9F02+ikiBgka2kH3WHKn6itOPWLm0cPLHuI48yE43fhXCy6xZKAFWS2z3UYAP0qa01hd+1LlWOOOck/VaAPbPDHiaO5ZI2KqeMK39K6m9is7+Irdwo6sMbjzXz9pmswSuRCy+auMhDnn6dRXf6F4nklVYmILA4CliCfpnigC7rXgO2kLyae0kanoqNwPwNcJqfhHULeRiiLIAfvJwR9RXp0WtRxv++MsJ9duR+nFWvtNreEPG9vc56j7hFAHiEdlfQyeXKIyD0JOxv8KuKkkKbLiN0UnkSKOnsRXperaXZzuPtNi0XJw6t0rlNV8Os3NrqRSMjG2Zc8/Uf4UAc3cQnaPs8vHUDd0/GobfRr6/JSaS7Kjp8/T9avyeHNcsv39skd7GD0iIzzWtZay8abb2xmiccEPHgfnQBmweFr6BT5rFkHPJAOKyNYc6a5WBrpZfRcbTXWXEq3o3W7XMR9pNwrFuI1jl3SyiR16h4/6igDj7rVtTuEZJlPlnjcVXP6CsOWWNEIZpGb/dwa7XVre/f5oLiCJCeA0f8AXFYtxbxzxbL/AA+0dYlxQBzU72SAO7XW/sFYD+tSWqPc4MUssCdmmlzkfhT20i1uJCLeJyw6CRsCpk0q6Rds8bCMdNke+gCaXNmmz+01mY9lc4/lWTdXF5K3krbJIh/5atyAa3LHRINw81bhwTyFhI/lWnPDFaWjpYaVchyMB2i/XmgDz25soYvnu2B7kgnA/CtjRtQgUqlrHbZ45Ydf0qjqkOsT3Hli2MiE9XRf1wauafBPpxDTSRI392ONB+poA6ORvtUY81lGR/CuKxdQsXXPkRySqT90dPzzWpFdS3S7UafcTwAOP0FMHh+/llaZ3kVDzkt/jQByLxTCRY1jgiGcYQBj+ZrqbHw8ZUXzb3bGf4NnWp4/DtzJIdgmPvjA/Ougt9PsNKgL3Ft9pmX5sGXrQBBZ+GrGdRFNdDy+jbSBj8uK6q2stJ0OzVoGigjGB5sg3s34ngfgKwrbU7m5UC1srezg9UhLN/303FO1S8s3ttl0Xlfrktk/kKANufxDGIWZHnCEYBGF3Vyd7rkt1vAjZYsY3yPnP4Cub1rXCqnyEmWNRgGUbVrO07Wm25d1mftsXCj86AN+e9msojN5i28X/PQrlj7Ba5PxdqjXq2UsUU67N+XkOWbOOSO1T6prcbBmZhJIOMdQtc1d3kkrpINytk8k5zQA8vHd/OQEmXkkcA/4Vuaa0s1sJYLhsocEE5Yfh3Fc5IyyBSy+U/UOvQ/4VLZ3JtJQzKD/ALSnH8qAOvjuJE2i6UhG/wCWqD5fx9KW5nm8vFvcROp5CznK/ge1Y1vrMsWCm8K3fG5T9RU8VxDclmaFCOrCMZ/Haen4UAXLeR55B5ivC5wPkkwT/RvxrchuJ0CmG6iYL/BIMMfxrnxY6XfITbXKwTA8KXIGfx6U6K1vIUC3aeYAM7kIYmgDsNO1Hc24pIjgdm712uja/M0YdfPBXGc4J/I15VZXVpGwBDRSgY+bK5/Cuv0W6SQETJPCo6Mq71P4UAe66FcQ6rZ/eglI4OV2MOKg1C0+xyebFJLCO+3DAfga840zUHtJN1rcRjHOY3ZfzU1oXXiy7ljZGKNJ03EcUAep6ZJZXNuoWRGfHzHcBn8KmWytomLiNEJ6kjg14wmuApiR445ep+XA/Aip9N8ZXUTtEZvNToed39aAPXNmmtJ5b6Vbkt/H5YwfqanOjaW0ZP8AZsTZ7RmvKbrXZGYSxSRo3oykf/Wqpc+J7oW+1synv9n4YUAeuDT7RRttUmhPTYXIFW4NMtlUvLHubvu+YfrXlGjeJZ9w33KgYGBLJuP5V0uk+JHWZjcwyop7h8qfwzQBv6nb7WJtIrKRc/dKZxWdLpFrOQ13plkzdc7B/hWrpmu2Tv8A6PayiQ/eZgADW7IFdFkd9gIzgjNAHGHRbB8yx6Talh/EsQ3fhxWhp2jQSKStrLEffA/pWldX3lkfZ/LAHXArHvvFJtJQsgaQ/wDTMZ/rQBtQ6ZBCdrGHd02kAn9adItrZLu8qLcOfkGTXMvr0FxJ56Q+W39+YYNY134jRNRT7RqSmM/eEaE/rjigDr5dfuGb9xbBEA+9M5X9Kp3XilA21Zd8g6iPpn65rn9R8SaO0BEcLXR/6avgH8BXNyX0lzKTDIsMeeEjTAH50Ads/iWZ1JlWNV9zxWRrerRyKTJdvJgcRRnC/kDWNLG7rtuJlZewdv8A9VYWsJcQK32eJFQD7w4/SgCprWvR2zNIllKzMcDHWsOLxTcT3BjRJI8HoTtFVr3WDbq6/Zg82cFnbHH4Vyt9rPknzLjYN3ZFwP8A69AHeXdxCyh764ErngRIck/rXP6vexqpS2higT1GM49zXOW+pW7HeS5z0O3J/Cq2q6ohgZIYsKerzMT+goApalqzSSNFbMOvzSDnNFZcV0isd2AP9lcZooA6q1/fHbL83Gc96jdF/eMBgqe1FFAEy3c81oFeQnA4PeomgjkgjlK4fJ+6cUUUAa9hM9s6su1ycffUH9etdUsryeSN7JuwcoSCPpRRQB3vh26nh2hpWmAOMS/NkV6EmlWVxp8V0YFjmdQSY/loooAhsb6eOfyWcSJux+8GTWzLY2l43lz20RDDGQuDRRQBlnwxp2+QoJoyOhSQjvXM61C2lzkW88zKxIIlIb+lFFAFSKyt7iJ5miRZB3QYrI1CUIWiaKKRQM/OvP50UUActexxrNuSNUyegJx/OmXNvAFTESfMOfeiigCO3sra0QzwwR785+ZQR+tTxapK3ymG2wDj/VCiigAutWnszGsCQqGxn5KluNTme2LSLG5IHBBx/OiigDlJruS7ldWCRgHjy1ArObT4ZGZ3MjMvQlqKKAOl8NaXBMymV5WJ4yWzXrGgeCNHeON5EmdigPzP/wDWoooAy/EGl2kNysUcWF3Y5JJqpNbwWcRa3giVuPmKgn9aKKAOW8UW6TwGWdnkO4fKWO0fgK46S8mt1kaEhMcABRRRQBg3cf262ea6ZpGUnAJ4HFcnNKzk9FAHRelFFAESDLgHvV1IEkTLZz9faiigBsI2grklT2NMCDqMr9KKKALcUrCHGAR9OtQSFj8wdgSexoooAntbuWHOCGz/AHhmtmz1OQQgiKEH2BH6ZoooADqks6GOaKF191P+NGnaxd2chFvIVXpt3MR/OiigDYTxRfhgcRZ9fmz/ADon8W6iSAVtyDwcoT/WiigCnd+I72YKsoiYDoCD/jVhNemkjIa2tSccNhs/+hUUUAQW2vXkUrD5XX+65YgfrVz/AISG8UK0axoT12lv/iqKKALsXiWcAk2Viz4+8VfP/oVW9O8earAcLDZsM9GRv/iqKKAOj0z4m6yhXbbaf/3xIP5PWrcfF/xEqBFg08DGOFk/+LoooAyJfifrayf8e9i2eTuWRv5vUk3xS1kRjZZ6Yh7lYnB/9DoooAzZ/H+p3BzLa2DHPdHP82rB1fxlqUki/JboPRVbH/oVFFAEC+Lr9kOYrXI4B2Ef1psPirUSxyY/zb/GiigBi+MdUhkJXySc8Fgxx+tU77xhrF65Se4GwjGFBH9aKKAMy4v5ZUYyBXPXkn/GsuS5llchiAF6ADFFFAEy3skaYQIB9Kq3NxJMCjEBT6CiigCr5S+pooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intracardiac ultrasound examination shows a stenotic mitral valve with some leaflet thickening and a hockey-stick appearance of the anterior mitral valve leaflet.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_14_37088=[""].join("\n");
var outline_f36_14_37088=null;
var title_f36_14_37089="Outward rotation PI";
var content_f36_14_37089=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F53514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F53514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Outward rotation exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hold your elbows at 90 degrees, close to your sides; holding a towel between your torso and the inside of your elbow will cue you to keep your elbow by your side. Hold one end of a rubber band in each hand and rotate the affected forearm outward two or three inches, holding for five seconds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_14_37089=[""].join("\n");
var outline_f36_14_37089=null;
var title_f36_14_37090="Pleural lipoma I CT";
var content_f36_14_37090=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Pleural lipoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 221px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: Chest radiograph shows a pleural mass in the left upper hemithorax. Right panel: CT scan shows a left upper pleural mass with homogeneous fatty content.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_14_37090=[""].join("\n");
var outline_f36_14_37090=null;
var title_f36_14_37091="Potassium citrate (powder or solution): Patient drug information";
var content_f36_14_37091=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Potassium citrate (powder or solution): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/55/26483?source=see_link\">",
"     see \"Potassium citrate (powder or solution): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/40/40579?source=see_link\">",
"     see \"Potassium citrate (powder or solution): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cytra-K",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat acid problems in the blood.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower acid levels in the urine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702769",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to potassium citrate, citric acid, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High potassium level. Signs include feeling weak, lightheaded, dizzy, feel like passing out, or have numbness or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695909",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with meals and at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with water and drink.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11409 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-F770B2E4D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_14_37091=[""].join("\n");
var outline_f36_14_37091=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212994\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014975\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014974\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014979\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014980\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014982\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014977\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014978\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014983\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014984\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/55/26483?source=related_link\">",
"      Potassium citrate (powder or solution): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/40/40579?source=related_link\">",
"      Potassium citrate (powder or solution): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_14_37092="Balsalazide: Pediatric drug information";
var content_f36_14_37092=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Balsalazide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?7/53/8021?source=see_link\">",
"    see \"Balsalazide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/55/31604?source=see_link\">",
"    see \"Balsalazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Colazal&reg;;",
"     </li>",
"     <li>",
"      Giazo&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F999761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       5-Aminosalicylic Acid Derivative",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F999790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/53/8021?source=see_link\">",
"      see \"Balsalazide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;5 years and Adolescents &le;17 years:",
"     <b>",
"      Ulcerative colitis:",
"     </b>",
"     Oral: Capsules: 2.25 g/day or 6.75 g/day for up to 8 weeks administered as either:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.25 g (three 750 mg capsules) 3 times daily (total daily dose: 6.75 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (one capsule) 3 times daily (total daily dose: 2.25 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Limited blinded clinical trial in children did not demonstrate significant improvement between total daily doses of 6.75 g or 2.25 g (Quiros, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &ge;18 years and Adults:",
"     <b>",
"      Ulcerative colitis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule: 2.25 g (three 750 mg capsules) 3 times daily for up to 8-12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet (Giazo&trade;): Males: 3.3 g (three 1.1 g tablets) twice daily for up to 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     There are no dosage adjustments provided in manufacturer&rsquo;s labeling. Renal toxicity has been observed with other 5-aminosalicylic acid products; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F139002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as disodium: 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colazal&reg;: 750 mg [contains sodium ~86 mg/capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as disodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Giazo&trade;: 1.1 g [contains sodium ~126 mg/tablet]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F138989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3423778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsules: Should be swallowed whole or may be opened and sprinkled on applesauce. Applesauce mixture may be chewed; swallow immediately, do not store mixture for later use. When sprinkled on food, may cause staining of teeth or tongue. Color variation of powder inside capsule (ranging from orange to yellow) is expected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Administer with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F999780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F999762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsules: Short-term treatment of mildly to moderately active ulcerative colitis (FDA approved in ages &ge;5 years and adults); Pediatric patients (5-17 years): 8 weeks of therapy; Adult patients: 12 weeks of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets (Giazo&trade;): Short-term treatment  (8 weeks) of mildly to moderately active ulcerative colitis (FDA approved in males &ge;18 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F139041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Colazal&reg; may be confused with Clozaril&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F139039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, fever, headache (more common in children than adults), insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (more common in children than adults), anorexia, cramps, constipation, diarrhea, dyspepsia, flatulence, hematochezia, nausea, stomatitis, ulcerative colitis exacerbation, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, musculoskeletal pain, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, pharyngolaryngeal pain, pharyngitis, respiratory infection, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening: Alopecia, alveolitis, AST increased, back pain, blood pressure increased, cholestatic jaundice, cirrhosis, defecation urgency, dizziness, dyspnea, edema, erythema nodosum, facial edema, fever, gastroenteritis, gastroesophageal reflux, hard stool, heart rate increased, hepatocellular damage, hepatotoxicity, hyperbilirubinemia, hypersensitivity, interstitial nephritis, jaundice, Kawasaki-like syndrome, lethargy, liver failure, liver necrosis, liver function tests increased, malaise, myocarditis, pain, pancreatitis, pericarditis, pleural effusion, pneumonia (with and without eosinophilia), pruritus, rash, renal failure, vasculitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F999766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to balsalazide or metabolites, salicylates, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10096390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; renal toxicity has been observed with other mesalamine (5-aminosalicylic acid) products. Patients with pyloric stenosis may have prolonged gastric retention, delaying release of drug in the colon. May cause staining of teeth or tongue if capsule is opened and sprinkled on food. Children may experience a higher frequency of some adverse effects than adults, including: Headache (15% vs 8%), abdominal pain (~13% vs 6%), and vomiting (10% vs &le;4%)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F999767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May exacerbate symptoms of ulcerative colitis; reported incidence higher in children than adults (6% vs 1%). May cause an acute intolerance syndrome (cramping, acute abdominal pain, bloody diarrhea; sometimes fever, headache, rash); discontinue if this occurs. Hepatoxicity (some cases fatal) including increased liver function tests, jaundice, cholestatic jaundice, cirrhosis, and hepatocellular damage, including liver necrosis and failure, has been reported with products that contain mesalamine or are metabolized to mesalamine, including balsalazide. Giazo&trade; oral tablets were not found effective in adult female patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F138997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: 5-ASA Derivatives may decrease the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin: 5-ASA Derivatives may enhance the adverse/toxic effect of Heparin. Specifically, the risk for bleeding/bruising may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin (Low Molecular Weight): 5-ASA Derivatives may enhance the adverse/toxic effect of Heparin (Low Molecular Weight). Specifically, the risk for bleeding/bruising may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiopurine Analogs: 5-ASA Derivatives may decrease the metabolism of Thiopurine Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varicella Virus-Containing Vaccines: 5-ASA Derivatives may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The primary concern is the potential development of Reye's Syndrome, a condition that has been associated with the use of salicylates in children with varicella infections.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F138999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F139008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Mesalamine (5-aminosalicylic acid) is the active metabolite of balsalazide; mesalamine is known to cross the placenta.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16040082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Improvement or worsening of symptoms; renal function (prior to initiation, then periodically); liver function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F999781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Balsalazide is a prodrug, converted by bacterial azoreduction to mesalamine [5-aminosalicylic acid (5-ASA)]. Mesalamine (5-aminosalicylic acid) is the active component of sulfasalazine; the specific mechanism of action of mesalamine is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes; action appears topical rather than systemic",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10096397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Delayed; may require several days to weeks (2 weeks); similar in adults and children",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F999782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Very low and variable; in children, reported systemic absorption of 5-ASA (active) lower than adults (C",
"     <sub>",
"      max",
"     </sub>",
"     : 67% lower, AUC: 64% lower)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &ge;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Azoreduced in the colon to 5-aminosalicylic acid (active), 4-aminobenzoyl-&beta;-alanine (inert), and N-acetylated metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Primary effect is topical (colonic mucosa); therapeutic effect appears not to be influenced by the systemic half-life of balsalazide (1.9 hours) or its metabolites (5-ASA [9.5 hours], N-Ac-5-ASA [10.4 hours])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Capsule: 1-2 hours; Tablet: 0.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Feces (65% as 5-aminosalicylic acid, 4-aminobenzoyl-&beta;-alanine, and N-acetylated metabolites); urine (11.3% as N-acetylated metabolites); Parent drug: Urine or feces (&lt;1%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F999795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/55/31604?source=see_link\">",
"      see \"Balsalazide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capsules should be swallowed whole or may be opened and sprinkled on applesauce; may cause staining of teeth or mouth when capsules are opened and sprinkled on food instead of swallowed whole. Report abdominal pain, unresolved diarrhea, or severe headache  to prescriber. May cause dry mouth.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10096421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Balsalazide 750 mg is equivalent to mesalamine 267 mg.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Connell W and Miller A, &ldquo;Treating Inflammatory Bowel Disease During Pregnancy: Risks and Safety of Drug Therapy,&rdquo;",
"      <i>",
"       Drug Safety",
"      </i>",
"      , 1999, 21(4):311-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37092/abstract-text/10514022/pubmed\" id=\"10514022\" target=\"_blank\">",
"        10514022",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diav-Citrin O, Park YH, Veerasuntharam G, et al, &ldquo;The Safety of Mesalamine in Human Pregnancy: A Prospective Controlled Cohort Study,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1998, 114(1):23-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37092/abstract-text/9428214/pubmed\" id=\"9428214\" target=\"_blank\">",
"        9428214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dubinsky M, Abraham B, and Mahadevan U, &ldquo;Management of the Pregnant IBD Patient,&rdquo;",
"      <i>",
"       Inflamm Bowel Dis",
"      </i>",
"      , 2008, 14(12):1736-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37092/abstract-text/18626967/pubmed\" id=\"18626967\" target=\"_blank\">",
"        18626967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quiros JA, Heyman MB, Pohl JF, et al, \"Safety, Efficacy, and Pharmacokinetics of Balsalazide in Pediatric Patients With Mild-to-Moderate Active Ulcerative Colitis: Results of a Randomized, Double-Blind Study,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2009, 49(5):571-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37092/abstract-text/19633577/pubmed\" id=\"19633577\" target=\"_blank\">",
"        19633577",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scherl EJ, Pruitt R, Gordon GL, et al, \"Safety and Efficacy of a New 3.3 g b.i.d. Tablet Formulation in Patients With Mild-to-Moderately-Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study,\"",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 104(6):1452-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37092/abstract-text/19491859/pubmed\" id=\"19491859\" target=\"_blank\">",
"        19491859",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13082 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_14_37092=[""].join("\n");
var outline_f36_14_37092=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139019\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999761\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999790\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139002\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138989\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3423778\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999780\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999762\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139041\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139039\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999766\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10096390\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999767\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298812\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138997\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138999\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139008\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16040082\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999781\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10096397\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999782\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999795\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10096421\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13082\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13082|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/53/8021?source=related_link\">",
"      Balsalazide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/55/31604?source=related_link\">",
"      Balsalazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_14_37093="Alfacalcidol: Drug information";
var content_f36_14_37093=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alfacalcidol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/49/20245?source=see_link\">",
"    see \"Alfacalcidol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11820952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      One-Alpha&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F11820954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin D Analog",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F11821507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypocalcemia, secondary hyperparathyroidism, or osteodystrophy in chronic renal failure:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Predialysis patients:",
"     <b>",
"      Note:",
"     </b>",
"     Limit supplemental calcium to &le;500 mg/day (elemental calcium):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Initial: 0.25 mcg/day for 2 months; if necessary, may titrate dose upward in increments of 0.25 mcg/day every 2 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance (usual dose): 0.5 mcg/day; up to 1 mcg/day may be necessary to maintain desired serum calcium concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dialysis patients:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Initial: 1 mcg/day for up to 4 weeks; if necessary, may titrate dose upward in increments of 0.5 mcg/day every 2-4 weeks. Usual effective dose: 1-2 mcg/day; up to 3 mcg/day may be required in some patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance (usual dose): 0.25-1 mcg/day; dosing interval may be increased (every other day) in patients who develop hypercalcemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     In some studies, intermittent dosing (on dialysis days) in dialysis patients has been shown as efficacious as daily dosing (Tarrass, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Dialysis patients:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: 1 mcg per dialysis (2-3 times weekly); if inadequate response after 1 week, may titrate dose upward in weekly increments of 1 mcg per dialysis (maximum dose: 12 mcg/week). Total titration period should not exceed 6 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance: 1.5-12 mcg per week (divided equally between hemodialysis sessions); usual effective dose: 6 mcg/week.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15671343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F11821508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Predialysis patients: If hypercalcemia develops within the first 2 months of therapy reduce dose to 0.25 mcg every other day; at any other time during therapy,  reduce dose by 50% and discontinue all calcium supplements until serum calcium levels normalize.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Dialysis patients: Oral, I.V.: Discontinue immediately for hypercalcemia; may consider reintroducing therapy at a reduced dose after serum calcium levels normalize.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F11821726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     One-Alpha&reg;: 0.25 mcg, 1 mcg  [contains sesame oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     One-Alpha&reg;: 2 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     One-Alpha&reg;: 2 mcg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11820951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11821509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer oral solution (drops) and capsules with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Shake injection solution well prior to use and administer as bolus I.V. injection over 30 seconds at the end of each dialysis.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11820955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of hypocalcemia, secondary hyperparathyroidism, and osteodystrophy in patients with chronic renal failure",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11820949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Alfacalcidol may be confused with calcitriol, cholecalciferol, ergocalciferol, paricalcitol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11821492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Frequency not defined; as associated with Hypervitaminosis D:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Cardiac arrhythmia, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Headache, hyperthermia, psychosis (rare), somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Genitourinary: Nocturia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Hypercalcemia, hypercholesterolemia, hyperphosphatemia, libido decreased, polydipsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Anorexia, constipation, nausea, pancreatitis, taste abnormal, vomiting, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Bone pain, muscle pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Conjunctivitis, corneal calcification, photophobia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: BUN increased, polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Rhinorrhea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11820958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to 1-&alpha;-hydroxyvitamin D",
"     <sub>",
"      3",
"     </sub>",
"     , vitamin D or its analogues and derivatives, or any component of the formulation; hypercalcemia; hyperphosphatemia; evidence of vitamin D toxicity",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11821489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Excessive vitamin D: Excessive vitamin D administration may lead to over suppression of parathyroid hormone (PTH), progressive or acute hypercalcemia, hypercalciuria, hyperphosphatemia, and adynamic bone disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Avoid excessive dosing; routine monitoring of serum calcium is necessary to avoid hypercalcemia. Dose reduction or discontinuation of therapy may be necessary. Withhold calcium supplementation until calcium levels normalize. Discontinue use with hypercalcemia in dialysis patients; may reinstitute therapy at 50% of previous dose 1 week after calcium levels have normalized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperphosphatemia: Monitor serum phosphate; increase in serum phosphorous may require the use of higher doses of  phosphate-binding agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Antacids: Avoid use of magnesium-containing antacids due to risk of hypermagnesemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Digoxin: Use with caution; hypercalcemia may precipitate cardiac arrhythmias in patients taking digoxin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Vitamin D: Avoid use with other vitamin D products or derivatives.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11822195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Alfacalcidol may increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Vitamin D Analogs. More specifically, orlistat may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with orlistat.  If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after orlistat.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11820956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A decrease in litter size and birth weights has been observed in animal studies. Safety has not been established in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F11820957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F11821497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adequate dietary calcium is necessary for clinical response to vitamin D. Recommended daily allowance of calcium in adults: 800-1000 mg (from all sources of calcium intake such as dialysate, diet and calcium supplements).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11821516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum calcium and phosphorus: Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progression of CKD, and the use of treatments for CKD-mineral and bone disorders (KDIGO, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD stage 3: Every 6-12 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD stage 4: Every 3-6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD stage 5 and 5D: Every 1-3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Periodic 24-hour urinary calcium and phosphorus; magnesium; alkaline phosphatase every 12 months or more frequently in the presence of elevated PTH; creatinine, BUN, albumin; intact parathyroid hormone (iPTH) every 3-12 months depending on CKD severity; periodic ophthalmologic exams",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F11821515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corrected total serum calcium (K/DOQI, 2003): CKD stages 3 and 4: 8.4-10.2 mg/dL (2.1-2.6 mmol/L); CKD stage 5: 8.4-9.5 mg/dL (2.1-2.37 mmol/L); KDIGO guidelines recommend maintaining normal ranges for all stages of CKD (3-5D) (KDIGO, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphorus (K/DOQI, 2003): CKD stages 3 and 4: 2.7-4.6 mg/dL (0.87-1.48 mmol/L); CKD stage 5 (including those treated with dialysis): 3.5-5.5 mg/dL (1.13-1.78 mmol/L); KDIGO guidelines recommend maintaining normal ranges for CKD stages 3-5 and lowering elevated phosphorus levels toward the normal range for CKD stage 5D (KDIGO, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum calcium-phosphorus product (K/DOQI, 2003): CKD stage 3-5: &lt;55 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PTH: Whole molecule, immunochemiluminometric assay (ICMA): 1.0-5.2 pmol/L; whole molecule, radioimmunoassay (RIA): 10.0-65.0 pg/mL; whole molecule, immunoradiometric, double antibody (IRMA): 1.0-6.0 pmol/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Target ranges by stage of chronic kidney disease (KDIGO, 2009): CKD stage 3-5: Optimal iPTH is unknown; maintain normal range (assay-dependent); CKD stage 5D: Maintain iPTH within 2-9 times the upper limit of normal for the assay used",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F14190114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      1 Alpha Leo (BE);",
"     </li>",
"     <li>",
"      Alfa Caps (IN);",
"     </li>",
"     <li>",
"      Alfacan (CL);",
"     </li>",
"     <li>",
"      Alfadiol (PL);",
"     </li>",
"     <li>",
"      Alfarol (TW);",
"     </li>",
"     <li>",
"      Alpha D3 (AR, CZ, EE, GR, IL, IT, PH, PY, RU, SG, TH, TR, VE);",
"     </li>",
"     <li>",
"      Alphacal (GR);",
"     </li>",
"     <li>",
"      Bon-One (CL, HK, ID, MY, TH);",
"     </li>",
"     <li>",
"      Bondiol (DE);",
"     </li>",
"     <li>",
"      EinsAlpha (DE);",
"     </li>",
"     <li>",
"      Etalpha (AT, CL, CN, DK, FI, NL, NO, PT, RU, SE);",
"     </li>",
"     <li>",
"      Gr-Alfa (IN);",
"     </li>",
"     <li>",
"      Innosfen (BR);",
"     </li>",
"     <li>",
"      One-Alpha (GB, HK, IE, NZ, PL, RU, TH, TR, ZA);",
"     </li>",
"     <li>",
"      Onealfa (KP, TW);",
"     </li>",
"     <li>",
"      Ostidil-D3 (IT);",
"     </li>",
"     <li>",
"      QTR-Alfa (IN);",
"     </li>",
"     <li>",
"      Tevacidol (DE);",
"     </li>",
"     <li>",
"      Un Alfa (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11821701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alfacalcidol is rapidly converted to the active metabolite of vitamin D (1,25-dihydroxyvitamin D",
"     <sub>",
"      3",
"     </sub>",
"     ) in the liver, effectively bypassing renal metabolic conversion; promotes intestinal absorption of calcium and phosphorous, resorption of calcium from the bone, and possibly renal reabsorption of calcium",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11821498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration of effect on intestinal calcium absorption levels: 1,25-(OH)",
"     <sub>",
"      2",
"     </sub>",
"     D",
"     <sub>",
"      3",
"     </sub>",
"     : 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Extensively to vitamin D-binding protein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic to 1,25-(OH)",
"     <sub>",
"      2",
"     </sub>",
"     D",
"     <sub>",
"      3",
"     </sub>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 3 hours in renal insufficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak of active vitamin D levels: Oral: 12 hours; I.V.: 4 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hamdy N, Kanis JA, Beneton MN, et al, &ldquo;Effect of Alfacalcidol on Natural Course of Renal Bone Disease in Mild to Moderate Renal Failure,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1995, 310(6976):358-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37093/abstract-text/7677827/pubmed\" id=\"7677827\" target=\"_blank\">",
"        7677827",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 1. Evaluation of Calcium and Phosphorus Metabolism.\" Available at file://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide1.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 3. Evaluation of Serum Phosphorus Levels.\" Available at file://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide3.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 6. Serum Calcium and Calcium-Phosphorus Product.&rdquo; Available at  file://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide6.htm",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37093/abstract-text/14520607/pubmed\" id=\"14520607\" target=\"_blank\">",
"        14520607",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 8A. Active Vitamin D Therapy in Patients With Stages 3 and 4 CKD.\" Available at file://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide8A.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 8B. Vitamin D Therapy in Patients on Dialysis (CKD Stage 5).\" Available at file://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide8B.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, Part 4. Definition and Classification of Stages of Chronic Kidney Disease.\" Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/p4_class.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, \"KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD),\"",
"      <i>",
"       Kidney Int Suppl",
"      </i>",
"      , 2009, 76(S113):1-130.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37093/abstract-text/19644521/pubmed\" id=\"19644521\" target=\"_blank\">",
"        19644521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levin A, Hemmelgarn B, Culleton B, et al, &ldquo;Canadian Guidelines for the Management of Chronic Kidney Disease,&rdquo;",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2008, 179(11):1154-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37093/abstract-text/19015566/pubmed\" id=\"19015566\" target=\"_blank\">",
"        19015566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tarrass F, Yazidi A, Sif H, et al, &ldquo;A Randomized Trial of Intermittent Versus Continuous Oral Alfacalcidiol Treatment of Hyperparathyroidism in End-Stage Renal Disease,&rdquo;",
"      <i>",
"       Clin Nephrol",
"      </i>",
"      , 2006, 65(6):415-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37093/abstract-text/16792136/pubmed\" id=\"16792136\" target=\"_blank\">",
"        16792136",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16467 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7727F3B860-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_14_37093=[""].join("\n");
var outline_f36_14_37093=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11820952\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11820954\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821507\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671343\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671344\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821508\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821726\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11820951\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821509\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11820955\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11820949\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821492\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11820958\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821489\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298703\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822195\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11820956\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11820957\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821497\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821516\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821515\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190114\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821701\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821498\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16467\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16467|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/49/20245?source=related_link\">",
"      Alfacalcidol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_14_37094="Lisdexamfetamine: Pediatric drug information";
var content_f36_14_37094=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lisdexamfetamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?22/53/23382?source=see_link\">",
"    see \"Lisdexamfetamine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/44/31429?source=see_link\">",
"    see \"Lisdexamfetamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4425746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vyvanse&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10170113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vyvanse&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F6130519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Amphetamine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Central Nervous System Stimulant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F6130552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/53/23382?source=see_link\">",
"      see \"Lisdexamfetamine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;6 years and Adolescents:",
"     <b>",
"      Attention-deficit/hyperactivity disorder: Note:",
"     </b>",
"     Individualize dosage based on patient need and response to therapy. Administer at the lowest effective dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Manufacturer&rsquo;s labeling: Oral: Initial: 30 mg once daily in the morning; may increase in increments of 10 mg or 20 mg/day at weekly intervals until optimal response is obtained; maximum daily dose: 70 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Alternate dosing: Oral: Initial: 20 mg once daily;  may increase in increments of 10 or 20 mg/day at 3-7 day intervals until optimal response is obtained; maximum daily dose: 70 mg/",
"     <b>",
"      day",
"     </b>",
"     (AAP, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Attention-deficit/hyperactivity disorder: Note:",
"     </b>",
"     Individualize dosage based on patient need and response to therapy. Administer at the lowest effective dose. Oral: Initial: 30 mg once daily in the morning; may increase in increments of 10 mg or 20 mg/day at weekly intervals until optimal response is obtained; maximum daily dose: 70 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4425793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as dimesylate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vyvanse&reg;: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F4425748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F4425744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089823.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089823.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6130553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer in the morning with or without food; avoid afternoon doses to prevent insomnia. Swallow capsule whole, do not chew; capsule may be opened and the entire contents dissolved in glass of water; stir until dispersed completely and consume the resulting solution immediately; do not store solution; do not divide capsule; do not take less than 1 capsule daily.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F6130549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light; dispense in tightly-closed container.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6130520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of attention-deficit/hyperactivity disorder (ADHD) (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4425741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vyvanse&reg; may be confused with Visanne&reg;, ViVAXIM&reg;, Vytorin&reg;, Glucovance&reg;, Vivactil&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F4425763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Blood pressure increased (adults), heart rate increased (adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Affect lability (children), agitation (adults), anxiety (adults), dizziness (children), fever (children), insomnia, irritability (children), jitteriness (adults), restlessness (adults), somnolence (children), tic (children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Hyperhidrosis (adults), rash (children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain (children), anorexia (adults), appetite decreased (more common in children and adolescents), diarrhea (adults), nausea, vomiting (children), weight loss (more common in children and adolescents), xerostomia (more common in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Genitourinary: Erectile dysfunction (adults), libido decreased (adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Tremor (adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Dyspnea (adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Accommodation abnormal, aggression, anaphylactic reaction, angioedema, cardiomyopathy, depression, dermatillomania, diplopia, eosinophilic hepatitis, hallucination, hypersensitivity, logorrhea, mania, mydriasis, psychotic episodes, seizure, Stevens-Johnson syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Additional adverse reaction associated with amphetamines:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cardiovascular: Hypertension, MI, sudden death, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Central nervous system: Exacerbation of motor and phonic tics, overstimulation, stroke, Tourette's syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Dermatologic: Toxic epidermal necrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Gastrointestinal: Abnormal taste, constipation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6130543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity or idiosyncrasy to lisdexamfetamine, other sympathomimetic amines, or any component; concurrent use or use within 14 days of MAO inhibitors (hypertensive crisis may occur)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F6130585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hyperthyroidism, glaucoma, and agitated states. Prescriptions should be written for the smallest quantity consistent with good patient care to minimize possibility of overdose.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6130545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious cardiovascular events including sudden death may occur in patients with pre-existing structural cardiac abnormalities or other serious heart problems. Sudden death has been reported in children and adolescents; sudden death, stroke, and MI have been reported in adults. Avoid the use of amphetamines in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that could place patients at an increased risk to the sympathomimetic effects of amphetamines. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. The American Heart Association recommends that all children diagnosed with ADHD who may be candidates for medication, such as lisdexamfetamine, should have a thorough cardiovascular assessment prior to initiation of therapy. This assessment should include a combination of medical history, family history, and physical examination focusing on cardiovascular disease risk factors. An ECG is not mandatory but should be considered.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     If a child displays symptoms of cardiovascular disease, including chest pain, dyspnea, or fainting, parents should seek immediate medical care for the child. In a recent retrospective study on the possible association between stimulant medication use and sudden death in children, 564 previously healthy children who died suddenly in motor vehicle accidents were compared to a group of 564 previously healthy children who died suddenly. Two of the 564 (0.4%) children in motor vehicle accidents were taking stimulant medications compared to 10 of 564 (1.8%) children who died suddenly. While the authors of this study conclude there may be an association between stimulant use and sudden death in children, there were a number of limitations to the study and the FDA cannot conclude this information impacts the overall risk:benefit profile of these medications (Gould, 2009). In a large retrospective cohort study involving 1,200,438 children and young adults (aged 2-24 years), none of the currently available stimulant medications or atomoxetine were shown to increase the risk of serious cardiovascular events (ie, acute MI, sudden cardiac death, or stroke) in current (adjusted hazard ratio: 0.75; 95% CI: 0.31-1.85) or former (adjusted hazard ratio: 1.03; 95% CI: 0.57-1.89) users compared to nonusers. It should be noted that due to the upper limit of the 95% CI, the study could not rule out a doubling of the risk, albeit low (Cooper, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Stimulant medications may increase blood pressure (average increase 2-4 mm Hg) and heart rate (average increase 3-6 bpm); some patients may experience greater increases; use stimulant medications with caution in patients with hypertension, heart failure, recent MI, advanced arteriosclerosis, ventricular arrhythmia, and other cardiovascular conditions that may be exacerbated by increases in blood pressure or heart rate.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Psychiatric adverse events may occur. Stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychosis. New-onset psychosis or mania may occur with stimulant use in patients without a prior history of psychotic illness or mania, even at standard doses. Stimulants may induce mixed/manic episodes in patients with bipolar disorder; patients should be screened for bipolar disorder prior to treatment; consider discontinuation if such symptoms (eg, delusional thinking, hallucinations, or mania) occur. May be associated with aggressive behavior or hostility (monitor for development or worsening of these behaviors).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Long-term effects in pediatric patients have not been determined. Use of stimulants in children has been associated with growth suppression; in pediatric clinical trials after 4 weeks of therapy, higher lisdexamfetamine doses were associated with greater weight loss; adolescents may experience larger weight loss than children; monitor growth; treatment interruption may be needed. Appetite suppression may occur; monitor weight during therapy, particularly in children.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Stimulants may lower seizure threshold leading to new-onset or breakthrough seizure activity; use with caution in patients with a history of seizure disorder. Visual disturbances (difficulty in accommodation and blurred vision) have been reported. May  exacerbate motor and phonic tics and Tourette's syndrome.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     CNS stimulants, including lisdexamfetamine, possess a high potential for abuse",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; assess for risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; use with caution in patients with history of ethanol or drug abuse; misuse may cause sudden death and serious cardiovascular adverse events. Prolonged administration may lead to drug dependence; abrupt discontinuation following high doses or for prolonged periods may result in symptoms of withdrawal; avoid abrupt discontinuation in patients who have received amphetamines for prolonged periods. Amphetamines may impair the ability to engage in potentially hazardous activities.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause hypersensitivity reactions including anaphylaxis, Stevens-Johnson syndrome, angioedema, and urticaria.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F4425767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alkalinizing Agents: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Amphetamines may enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihistamines: Amphetamines may diminish the sedative effect of Antihistamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethosuximide: Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Amphetamines may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Amphetamines may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Amphetamines may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6130548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acidic foods, juices, or vitamin C may decrease GI absorption. Food does not affect the extent of absorption (ie, AUC of dextroamphetamine); a high-fat meal delays the time to peak concentration of dextroamphetamine by 1 hour",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F4425752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4425753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects have not been observed in animal reproduction studies. Lisdexamfetamine is converted to dextroamphetamine. The majority of human data is based on illicit amphetamine/methamphetamine exposure and not from therapeutic maternal use (Golub, 2005). Use of amphetamines during pregnancy may lead to an increased risk of premature birth and low birth weight; newborns may experience symptoms of withdrawal. Behavioral problems may also occur later in childhood (LaGasse, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6130554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evaluate patients for cardiac disease prior to initiation of therapy with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment. Monitor CNS activity; blood pressure and heart rate (baseline, following dose increases, and periodically during treatment), sleep, appetite, abnormal movements, height, weight, BMI, growth in children. Patients should be re-evaluated at appropriate intervals to assess continued need of the medication. Observe for signs/symptoms of aggression or hostility, or depression. Monitor for visual disturbances. Monitor for signs of misuse, abuse, and addiction.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6130550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lisdexamfetamine dimesylate is a prodrug that is converted to the active component dextroamphetamine (an amphetamine). Amphetamines are noncatecholamine, sympathomimetic amines that promote the release of catecholamines (primarily dopamine and norepinephrine) from their storage sites in the presynaptic nerve terminals, thus increasing the amounts of circulating dopamine and norepinephrine in the cerebral cortex and reticular activating system. A less significant mechanism may include their ability to block the reuptake of catecholamines by competitive inhibition. Amphetamines also weakly inhibit the action of monoamine oxidase. They peripherally increase blood pressure and act as a respiratory stimulant and weak bronchodilator.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F16117614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 1 hour (AAP, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration of action: 10-12 hours (AAP, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6130551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Dextroamphetamine: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3.5-4.6 L/kg; distributes into CNS; mean CSF concentrations are 80% of plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Metabolized in the blood by hydrolytic activity of red blood cells to dextroamphetamine and l-lysine; not metabolized by CYP P450",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Lisdexamfetamine: &lt;1 hour; dextroamphetamine: 10-13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lisdexamfetamine: Children 6-12 years: 1 hour (fasting)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dextroamphetamine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6-12 years: 3.5 hours (fasting)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 3.8 hours (fasting), 4.7 hours (after a high-fat meal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (96%; 42% of dose as amphetamine, 2% as lisdexamfetamine, 25% as hippuric acid); feces (minimal)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F6130556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/44/31429?source=see_link\">",
"      see \"Lisdexamfetamine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide received with each prescription and refill of dextroamphetamine. Serious cardiac effects or psychiatric adverse effects may occur; notify physician of any heart problems, high blood pressure, or psychiatric conditions before starting therapy. May reduce the growth rate in children and has been associated with worsening of aggressive behavior; notify physician if child displays aggression or hostility. Ensure that physician monitors child&rsquo;s weight and height. May impair ability to perform activities requiring mental alertness or physical coordination. May be habit-forming; avoid abrupt discontinuation after prolonged use. Limit caffeine; avoid alcohol and the herbal medicine St. John's wort. May cause dry mouth.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F6130713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment for ADHD should include &ldquo;drug holiday&rdquo; or periodic discontinuation in order to assess the patient's requirements, decrease tolerance, and limit suppression of linear growth and weight. Medications used to treat ADHD should be part of a total treatment program that may include other components such as psychological, educational, and social measures.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, \"ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2011,128(5):1007-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37094/abstract-text/22003063/pubmed\" id=\"22003063\" target=\"_blank\">",
"        22003063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD; available at: file://americanheart.mediaroon.com/index.php?s=43&amp;item=422.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists (ACOG) Committee Opinion: No. 479, &ldquo;Methamphetamine Abuse in Women of Reproductive Age,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2011, 117(3):751-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37094/abstract-text/21343793/pubmed\" id=\"21343793\" target=\"_blank\">",
"        21343793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Biederman J, Krishnan S, Zhang Y, et al, \"Efficacy and Tolerability of Lisdexamfetamine Dimesylate (NRP-104) in Children With Attention-Deficit/Hyperactivity Disorder: A Phase III, Multicenter, Randomized, Double-Blind, Forced-Dose, Parallel-Group Study,\"",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2007, 29(3):450-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37094/abstract-text/17577466/pubmed\" id=\"17577466\" target=\"_blank\">",
"        17577466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Habel LA, Sox CM, et al, &ldquo;ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(20):1896-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37094/abstract-text/22043968/pubmed\" id=\"22043968\" target=\"_blank\">",
"        22043968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Golub M, Costa L, Crofton K, et al, \"NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Amphetamine and Methamphetamine,\"",
"      <i>",
"       Birth Defects Res B Dev Reprod Toxicol",
"      </i>",
"      , 2005, 74(6):471-584.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37094/abstract-text/16167346/pubmed\" id=\"16167346\" target=\"_blank\">",
"        16167346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould MS, Walsh BT, Munfakh JL, et al, \"Sudden Death and Use of Stimulant Medications in Youths,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2009, 166(9):992-1001.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37094/abstract-text/19528194/pubmed\" id=\"19528194\" target=\"_blank\">",
"        19528194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LaGasse LL, Derauf C, Smith LM, et al, \"Prenatal Methamphetamine Exposure and Childhood Behavior Problems at 3 and 5 Years of Age,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2012, 129(4):681-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37094/abstract-text/22430455/pubmed\" id=\"22430455\" target=\"_blank\">",
"        22430455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nissen SE, &ldquo;ADHD and Cardiovascular Risk,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354:1445-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37094/abstract-text/16549404/pubmed\" id=\"16549404\" target=\"_blank\">",
"        16549404",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pliszka S and AACAP Work Group on Quality Issues, &ldquo;Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2007, 46(7):894-921.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37094/abstract-text/17581453/pubmed\" id=\"17581453\" target=\"_blank\">",
"        17581453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson CH, et al,  &ldquo;Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs. A Scientific Statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117:2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/14/37094/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13015 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_14_37094=[""].join("\n");
var outline_f36_14_37094=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709015\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425746\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10170113\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6130519\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6130552\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425793\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425748\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425744\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874689\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6130553\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6130549\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6130520\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425741\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425763\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6130543\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6130585\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6130545\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299610\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425767\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6130548\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425752\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425753\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6130554\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6130550\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16117614\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6130551\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6130556\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6130713\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13015\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13015|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/53/23382?source=related_link\">",
"      Lisdexamfetamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/44/31429?source=related_link\">",
"      Lisdexamfetamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_14_37095="Nodular regenerative hyperplasia of the liver";
var content_f36_14_37095=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nodular regenerative hyperplasia of the liver",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/14/37095/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/14/37095/contributors\">",
"     Wissam Bleibel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/14/37095/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/14/37095/contributors\">",
"     Michael P Curry, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/14/37095/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/14/37095/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/14/37095/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/14/37095/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/14/37095/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodular regenerative hyperplasia (NRH) of the liver is an uncommon condition characterized by diffuse benign transformation of the hepatic parenchyma into small regenerative nodules with minimal or no fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In the past it has also been referred to as nodular transformation, noncirrhotic nodulation, and partial nodular transformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/3\">",
"     3",
"    </a>",
"    ]. NRH affects mainly patients older than 60, although rare cases have been reported in children and even fetuses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NRH belongs to a group of liver diseases that causes an intrahepatic form of noncirrhotic portal hypertension (NCPH). In addition to NRH, this group includes incomplete septal cirrhosis and hepatoportal sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/5\">",
"     5",
"    </a>",
"    ]. The etiologic and histopathologic similarities that NRH shares with these conditions suggest that they are pathophysiologically related; the histological differences probably reflect chronologic progression of a single disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/5-9\">",
"     5-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NRH is the main cause of noncirrhotic portal hypertension in the western world and is responsible for 14 to 27 percent of cases of NCPH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/4,6,10\">",
"     4,6,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/40/14985?source=see_link\">",
"     \"Noncirrhotic portal hypertension: Portal fibrosis and schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of NRH in the general population has varied in different reports. Precise estimates are uncertain, in part because most patients are asymptomatic and because the diagnosis is not always established.",
"   </p>",
"   <p>",
"    Autopsy studies have shown an overall prevalence of 0.72 to 2.6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/1,2,11,12\">",
"     1,2,11,12",
"    </a>",
"    ]. NRH is probably more common in the elderly. This was suggested in an autopsy study of 2500 individuals in which the prevalence was approximately 6 percent in individuals over 80 years, which was sevenfold higher than patients 60 years or younger [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, liver biopsy studies report a prevalence of less than 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NRH affects men and women equally. A familial form has been reported in six siblings of three unrelated families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LIVER PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;On gross examination, NRH is characterized by diffuse fine granulations with nodules usually measuring 1 to 3 mm in diameter, although they may rarely be up to 10 to 15 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. The liver is typically of normal size and looks similar to micronodular cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/7,16\">",
"     7,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On microscopic examination, the nodules are clustered around the portal triads [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The central part of the regenerative nodule consists of hypertrophied hepatocytes arranged in multilayer (two to three layers) plates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Approximately 40 percent of these cells show dysplastic features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. By contrast, cells in the periphery are thin, atrophic, and arranged in parallel plates associated with some sinusoidal dilatation (",
"    <a class=\"graphic graphic_picture graphicRef54880 graphicRef76034 \" href=\"mobipreview.htm?15/4/15434\">",
"     picture 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A distinguishing feature of NRH is the absence of fibrosis between the nodules, although fibrosis is occasionally seen in the periportal or perisinusoidal areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. The small portal venous radicals may be occluded or even absent. In many cases, the central veins are compressed by the hypertrophied hepatocytes or they show evidence of veno-occlusive changes. Inflammatory features are minimal or absent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/8,16\">",
"     8,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The findings of NRH can be easily missed on hematoxylin and eosin (H&amp;E) and trichrome staining. A reticulin stain is necessary to clearly demonstrate the characteristic findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/2,16-18\">",
"     2,16-18",
"    </a>",
"    ]. NRH may be overlooked when a relatively small-caliber core biopsy is obtained, reticulin stain is not used, or the pathologist is unfamiliar with the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many etiologic factors have been associated with the development of NRH (",
"    <a class=\"graphic graphic_table graphicRef50663 \" href=\"mobipreview.htm?25/27/26045\">",
"     table 1",
"    </a>",
"    ). Most of these are known to cause vascular damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ]. Disorders leading to thrombophilia are most common, as hypercoagulability has been identified in up to 50 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/9\">",
"     9",
"    </a>",
"    ]. Many other patients have autoimmune, myeloproliferative, or lymphoproliferative diseases.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A few studies indicate an association between NRH and primary biliary cirrhosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/2,19\">",
"       2,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      NRH associated with portal hypertension has been described in patients with HIV infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. An association with a hypercoagulable tendency and use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      has been reported in such patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      NRH has been described in patients with common variable immunodeficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/23-25\">",
"       23-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      NRH has been observed in approximately 6 percent of patients with systemic lupus erythematosus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Many myeloproliferative and lymphoproliferative disorders and other malignancies are associated with NRH. This could be due to the thrombophilia developing secondary to malignancy, from direct invasion of the tumor into the portal veins leading to thrombosis, or from the chemotherapy regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/17,28-32\">",
"       17,28-32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      NRH has been described in patients who have undergone organ transplantation. Infection with cytomegalovirus and the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      have been implicated in the pathogenesis in renal transplant recipients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/17\">",
"       17",
"      </a>",
"      ]. Postoperative hepatic vascular alterations and the use of azathioprine have been associated with NRH in liver transplant recipients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/5\">",
"       5",
"      </a>",
"      ]. NRH has also been reported in patients following bone marrow transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many aspects of the pathogenesis of NRH are unknown. One theory suggests that a central event is portal venopathy caused by thrombosis or obliteration due to hypercoagulability, endothelial injury, or autoimmune injury (from immune complex deposition, autoantibodies, or activated T-cells) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/4,5,8,28,33,34\">",
"     4,5,8,28,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A vascular cause of NRH is supported by experimental studies in animals and histologic findings in humans. Blockage of the portal veins decreases blood flow to the liver by 70 percent, thereby leading to ischemia of the supplied hepatic parenchyma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/7\">",
"     7",
"    </a>",
"    ]. This leads to atrophy of the more vulnerable regions around the central vein and compensatory hypertrophy of the less vulnerable periportal areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/2\">",
"     2",
"    </a>",
"    ]. Experimental ligation of a branch of the portal vein in rabbits leads to atrophy of the supplied portion of the liver and hypertrophy of the vascularized regions.",
"   </p>",
"   <p>",
"    Pathological studies of human livers with acute or chronic portal vein thrombosis have demonstrated apoptosis, atrophy, and the development of nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/7\">",
"     7",
"    </a>",
"    ]. In some cases, the primary insult to the liver was arterial rather than venous. The resulting periportal inflammation eventually leads to portal venopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/2,5,7,8,28,35,36\">",
"     2,5,7,8,28,35,36",
"    </a>",
"    ]. In a study of 107 liver biopsies from patients with NCPH, the underlying cause was considered to be idiopathic portal hypertension in 66 cases, incomplete septal cirrhosis in 25, NRH in 14, and partial nodular transformation in two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/6\">",
"     6",
"    </a>",
"    ]. All four groups had portal venous obliteration, suggesting that these conditions are pathogenically related.",
"   </p>",
"   <p>",
"    T-cell induced autoimmune mechanisms have also been implicated in the development of the portal vein injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/16\">",
"     16",
"    </a>",
"    ]. Sinusoidal infiltration with CD 8+ cytotoxic T cells was observed in 32 percent of 44 patients with NRH in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/33\">",
"     33",
"    </a>",
"    ]. The T cells were located mainly in the atrophic areas and were adjacent to endothelial cells exhibiting evidence of apoptosis. The authors speculated that transient T-cell induced endothelial injury may be the trigger for the development of NRH. Another study found that 77 percent of patients with NRH had antiphospholipid antibodies possibly indicating an antibody-dependent autoimmune mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with NRH are asymptomatic and have normal liver biochemical tests, although about 11 to 25 percent have mild nonspecific elevations, mainly alkaline phosphatase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/7,10,28\">",
"     7,10,28",
"    </a>",
"    ]. Hepatic function is usually preserved and liver failure with ascites",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    encephalopathy is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/7,28,38\">",
"     7,28,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proportion of patients with NRH who have portal hypertension is not known precisely but is probably highest in patients who present with a medical condition known to be associated with NRH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Hepatic synthetic function is usually preserved even when portal hypertension is clinically evident. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;NRH should be considered in patients with clinical signs of portal hypertension who do not have cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/7,16\">",
"     7,16",
"    </a>",
"    ]. The diagnosis requires histologic evaluation.",
"   </p>",
"   <p>",
"    Establishing the correct diagnosis is important for two reasons. In contrast to patients with cirrhosis, those with NRH have preserved hepatic function and are not known to develop liver failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    encephalopathy except for in very rare cases. In addition, NRH does not appear to be associated with an increased risk of hepatocellular carcinoma and thus surveillance is not warranted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/40/14985?source=see_link\">",
"     \"Noncirrhotic portal hypertension: Portal fibrosis and schistosomiasis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8\">",
"     'Natural history'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Ultrasonography (US) and computer tomography (CT) are of limited diagnostic value since the nodules of NRH are generally isoechoic on US and nonspecifically hypodense on CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/4,39\">",
"     4,39",
"    </a>",
"    ]. The nodules can also be hypoechoic on US, often with a hypoechoic rim, features that can mistakenly suggest hepatic metastases; nodules seen by these imaging techniques can also be mistaken for micronodular cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/16,40\">",
"     16,40",
"    </a>",
"    ]. Hepatic scintigraphy is also unhelpful in establishing the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/7\">",
"     7",
"    </a>",
"    ]. The evaluation should generally include an imaging test (such as Doppler US) to exclude portal vein thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The few studies that have evaluated the role of magnetic resonance imaging suggest it may improve visualization of the nodules compared with other imaging techniques. The nodules appear isointense on T2-weighted images and contain foci of high intensity on T1-weighted images [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/4,18,26,43\">",
"     4,18,26,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histological examination is considered essential for establishing the diagnosis of NRH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/16,40\">",
"     16,40",
"    </a>",
"    ]. Percutaneous or transjugular biopsy may not be sufficient because of the small size of the regenerative nodules. Thus, patients suspected of having NRH who have an unrevealing core needle biopsy may require an open or laparoscopic biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/2,7,16,44,45\">",
"     2,7,16,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatic vein catheterization and Doppler studies can help identify the cause of portal hypertension. The pressure measurements typically reveal an increase in the gradient between the free hepatic vein pressure and wedge pressure, indicating a sinusoidal pattern of portal hypertension. However, presinusoidal hypertension can also be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/2,7,41,46\">",
"     2,7,41,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with NRH should undergo evaluation for associated conditions if they have hematologic manifestations of myeloproliferative disease on the complete blood count and differential, prior thrombotic events that might reflect an underlying hypercoagulable state, or manifestations suggestive of a systemic disease associated with vascular injury (eg, vasculitis, lupus). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21322?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of the myeloproliferative neoplasms\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should also be evaluated for local portal tract inflammatory diseases (eg, primary biliary cirrhosis and sarcoidosis) if the histologic findings are suggestive of these disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41641?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of NRH is poorly understood. Most cases probably remain asymptomatic or progress slowly. The lesions of NRH tend to remain constant, although rarely they undergo rapid growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis appears to reflect the development and progression of portal hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/48\">",
"     48",
"    </a>",
"    ]. Studies of patients with NCPH (some of whom have NRH) have reported a five-year survival of 90 percent and a 30-year survival of 55 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/5,49\">",
"     5,49",
"    </a>",
"    ]. Rare cases of hepatic failure have been described and were probably due to progressive atrophy and increasing portosystemic shunting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/2,7,49\">",
"     2,7,49",
"    </a>",
"    ]. In an illustrative review, 31 percent of 42 patients with NRH developed portal hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/50\">",
"     50",
"    </a>",
"    ]. Of these, 26 percent had varices, and 12 percent developed variceal bleeding (one of whom died). The mean survival after diagnosis was eight years, although the mortality was rarely related to liver complications",
"   </p>",
"   <p>",
"    It is not clear whether NRH is a premalignant condition. There have been several reports of concomitant hepatocellular carcinoma (HCC), suggesting a possible pathogenic association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/47\">",
"     47",
"    </a>",
"    ]. However, the relationship between the NRH and the HCC is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. It is possible that tumor invasion of the portal venous system led to the development of NRH or that the HCC developed within dysplastic foci within the nodule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/12,29,47,51-59\">",
"     12,29,47,51-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of NRH is directed at withdrawing the offending agent if known, treating the underlying medical condition, and preventing and treating the complications. As an example, biochemical and histologic improvement or reversibility has been reported after stopping",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    in transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/18,60\">",
"     18,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other therapeutic modalities are aimed at the disease manifestations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of portal hypertension associated with NRH is based upon the experience in treating portal hypertension from other causes. Thus, beta-blockers, diuretics, variceal banding, and sclerotherapy may be used as indicated. Because hepatic synthetic function is preserved and encephalopathy is rare, portosystemic shunts and TIPS can be of significant therapeutic benefit in patients with complications related to portal hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/2,5,7,49\">",
"       2,5,7,49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/35/34359?source=see_link\">",
"       \"Indications for the use of transjugular intrahepatic portosystemic shunts\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Successful treatment of cholestasis with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"       ursodeoxycholic acid",
"      </a>",
"      has been described in a case report [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/48\">",
"       48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43526?source=see_link\">",
"       \"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Liver transplantation has been required in patients with severely complicated portal hypertension or liver failure. At least 37 cases of liver transplantation have been reported in the literature with 34 patients alive up to one year after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37095/abstract/5,13,21,28,49,61-65\">",
"     5,13,21,28,49,61-65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NRH should be considered in patients with portal hypertension who lack evidence of cirrhosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis requires a liver biopsy. The findings of NRH can be easily missed on hematoxylin and eosin and trichrome staining; reticulin staining and a high degree of suspicion are essential for establishing the diagnosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Evaluation should also include an imaging test (such as Doppler ultrasonography) to exclude portal vein thrombosis. Conditions associated with NRH should be sought including myeloproliferative and other hypercoagulable disorders, systemic diseases associated with vascular injury (eg, autoimmune diseases), and local portal tract inflammatory diseases (eg, primary biliary cirrhosis and sarcoidosis).",
"     </li>",
"     <li>",
"      There is no proven treatment for NRH. We suggest management focus on withdrawing the offending agent, if known; treating the underlying medical condition; and preventing and treating complications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/1\">",
"      Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990; 11:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/2\">",
"      Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 2006; 44:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/3\">",
"      Terminology of nodular hepatocellular lesions. International Working Party. Hepatology 1995; 22:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/4\">",
"      Mahamid J, Miselevich I, Attias D, et al. Nodular regenerative hyperplasia associated with idiopathic thrombocytopenic purpura in a young girl: a case report and review of the literature. J Pediatr Gastroenterol Nutr 2005; 41:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/5\">",
"      Krasinskas AM, Eghtesad B, Kamath PS, et al. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl 2005; 11:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/6\">",
"      Nakanuma Y, Hoso M, Sasaki M, et al. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology 1996; 28:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/7\">",
"      Al-Mukhaizeem KA, Rosenberg A, Sherker AH. Nodular regenerative hyperplasia of the liver: an under-recognized cause of portal hypertension in hematological disorders. Am J Hematol 2004; 75:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/8\">",
"      Ibarrola C, Colina F. Clinicopathological features of nine cases of non-cirrhotic portal hypertension: current definitions and criteria are inadequate. Histopathology 2003; 42:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/9\">",
"      Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut 2002; 51:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/10\">",
"      Naber AH, Van Haelst U, Yap SH. Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patients. J Hepatol 1991; 12:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/11\">",
"      Nakanuma Y. Nodular regenerative hyperplasia of the liver: retrospective survey in autopsy series. J Clin Gastroenterol 1990; 12:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/12\">",
"      Colina F, Alberti N, Solis JA, Martinez-Tello FJ. Diffuse nodular regenerative hyperplasia of the liver (DNRH). A clinicopathologic study of 24 cases. Liver 1989; 9:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/13\">",
"      Elariny HA, Mizrahi SS, Hayes DH, et al. Nodular regenerative hyperplasia: a controversial indication for orthotopic liver transplantation. Transpl Int 1994; 7:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/14\">",
"      Cancado EL, Medeiros DM, Deguti MM, et al. Celiac disease associated with nodular regenerative hyperplasia, pulmonary abnormalities, and IgA anticardiolipin antibodies. J Clin Gastroenterol 2006; 40:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/15\">",
"      Dumortier J, Boillot O, Chevallier M, et al. Familial occurrence of nodular regenerative hyperplasia of the liver: a report on three families. Gut 1999; 45:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/16\">",
"      Biecker E, Trebicka J, Fischer HP, et al. Portal hypertension and nodular regenerative hyperplasia in a patient with celiac disease. Z Gastroenterol 2006; 44:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/17\">",
"      O'Brien K, Hussain N, Warady BA, et al. Nodular regenerative hyperplasia and severe portal hypertension in cystinosis. Clin Gastroenterol Hepatol 2006; 4:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/18\">",
"      Seiderer J, Zech CJ, Diebold J, et al. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur J Gastroenterol Hepatol 2006; 18:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/19\">",
"      Colina F, Pinedo F, Sol&iacute;s JA, et al. Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis. Gastroenterology 1992; 102:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/20\">",
"      Mallet V, Blanchard P, Verkarre V, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007; 21:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/21\">",
"      Tateo M, Sebagh M, Bralet MP, et al. A new indication for liver transplantation: nodular regenerative hyperplasia in human immunodeficiency virus-infected patients. Liver Transpl 2008; 14:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/22\">",
"      Saifee S, Joelson D, Braude J, et al. Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection. Clin Gastroenterol Hepatol 2008; 6:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/23\">",
"      Ward C, Lucas M, Piris J, et al. Abnormal liver function in common variable immunodeficiency disorders due to nodular regenerative hyperplasia. Clin Exp Immunol 2008; 153:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/24\">",
"      De Boer NK, Tuynman H, Bloemena E, et al. Histopathology of liver biopsies from a thiopurine-na&iuml;ve inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia. Scand J Gastroenterol 2008; 43:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/25\">",
"      Malamut G, Ziol M, Suarez F, et al. Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol 2008; 48:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/26\">",
"      Horita T, Tsutsumi A, Takeda T, et al. Significance of magnetic resonance imaging in the diagnosis of nodular regenerative hyperplasia of the liver complicated with systemic lupus erythematosus: a case report and review of the literature. Lupus 2002; 11:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/27\">",
"      Colmegna I, deBoisblanc BP, Gimenez CR, Espinoza LR. Slow development of massive splenomegaly, portal and pulmonary hypertension in systematic lupus erythematosus: can nodular regenerative hyperplasia of the liver explain all these findings? Lupus 2005; 14:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/28\">",
"      Buchel O, Roskams T, Van Damme B, et al. Nodular regenerative hyperplasia, portal vein thrombosis, and avascular hip necrosis due to hyperhomocysteinaemia. Gut 2005; 54:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/29\">",
"      Kataoka TR, Tsukamoto Y, Kanazawa N, et al. Concomitant hepatocellular carcinoma and non-Hodgkin's lymphoma in a patient with nodular regenerative hyperplasia. Pathol Int 2006; 56:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/30\">",
"      Gonz&aacute;lez-Alegre MT, Guerra-Vales JM, Guti&eacute;rrez A, et al. Nodular regenerative hyperplasia of the liver and Hodgkin's disease: a case report. Acta Gastroenterol Belg 2004; 67:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/31\">",
"      Key NS, Kelly PM, Emerson PM, et al. Oesophageal varices associated with busulphan-thioguanine combination therapy for chronic myeloid leukaemia. Lancet 1987; 2:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/32\">",
"      Hubert C, Sempoux C, Horsmans Y, et al. Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? Liver Int 2007; 27:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/33\">",
"      Ziol M, Poirel H, Kountchou GN, et al. Intrasinusoidal cytotoxic CD8+ T cells in nodular regenerative hyperplasia of the liver. Hum Pathol 2004; 35:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/34\">",
"      Youssef WI, Tavill AS. Connective tissue diseases and the liver. J Clin Gastroenterol 2002; 35:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/35\">",
"      Podevin P, Spiridon G, Terris B, et al. Nodular regenerative hyperplasia of the liver after IL-2 therapy in an HIV-infected patient. AIDS 2006; 20:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/36\">",
"      Reynolds WJ, Wanless IR. Nodular regenerative hyperplasia of the liver in a patient with rheumatoid vasculitis: a morphometric study suggesting a role for hepatic arteritis in the pathogenesis. J Rheumatol 1984; 11:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/37\">",
"      Klein R, Goller S, Bianchi L. Nodular regenerative hyperplasia (NRH) of the liver--a manifestation of 'organ-specific antiphospholipid syndrome'? Immunobiology 2003; 207:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/38\">",
"      Seoane Urgorri A, Galeras Sadurni JA, Coll Estrada S, et al. [Ascites as the sole clinical manifestation in a patient with nodular regenerative hyperplasia]. Gastroenterol Hepatol 2003; 26:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/39\">",
"      Grattagliano A, Rapaccini GL, Caturelli E, et al. Nodular regenerative hyperplasia of the liver: ultrasonographic appearance and echo-guided bioptic diagnosis. Ital J Gastroenterol 1994; 26:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/40\">",
"      Clouet M, Boulay I, Boudiaf M, et al. Imaging features of nodular regenerative hyperplasia of the liver mimicking hepatic metastases. Abdom Imaging 1999; 24:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/41\">",
"      Shim SG, Sohn JH, Lee JW, et al. [A case of nodular regenerative hyperplasia of liver that mimicked primary biliary cirrhosis]. Korean J Hepatol 2004; 10:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/42\">",
"      Wanless IR. Noncirrhotic portal hypertension: recent concepts. Prog Liver Dis 1996; 14:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/43\">",
"      Rha SE, Lee MG, Lee YS, et al. Nodular regenerative hyperplasia of the liver in Budd-Chiari syndrome: CT and MR features. Abdom Imaging 2000; 25:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/44\">",
"      Krastev N, Grigorov N, Dinkov L, et al. [The role of laparoscopy and laparoscopic ultrasonography in the diagnosis and differential diagnosis of nodular hepatocellular lesions]. Khirurgiia (Sofiia) 1998; 53:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/45\">",
"      Trauner M, Stepan KM, Resch M, et al. Diagnostic problems in nodular regenerative hyperplasia (nodular transformation) of the liver. Review of the literature and report of two cases. Z Gastroenterol 1992; 30:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/46\">",
"      Ueno S, Tanabe G, Sueyoshi K, et al. Hepatic hemodynamics in a patient with nodular regenerative hyperplasia. Am J Gastroenterol 1996; 91:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/47\">",
"      Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma and nodular regenerative hyperplasia: possible pathogenetic relationship. Am J Gastroenterol 1996; 91:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/48\">",
"      Faust D, Fellbaum C, Zeuzem S, Dietrich CF. Nodular regenerative hyperplasia of the liver: a rare differential diagnosis of cholestasis with response to ursodeoxycholic acid. Z Gastroenterol 2003; 41:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/49\">",
"      Henderson, JM. Liver transplantation for severe intrahepatic non-cirrhotic portal hypertension. Liver Transpl 2005; 11:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/50\">",
"      Morris JM, Oien KA, McMahon M, et al. Nodular regenerative hyperplasia of the liver: survival and associated features in a UK case series. Eur J Gastroenterol Hepatol 2010; 22:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/51\">",
"      Wanless IR. Nodular regenerative hyperplasia, dysplasia, and hepatocellular carcinoma. Am J Gastroenterol 1996; 91:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/52\">",
"      S&oslash;gaard PE. Nodular transformation of the liver, alpha-fetoprotein, and hepatocellular carcinoma. Hum Pathol 1981; 12:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/53\">",
"      Kobayashi S, Saito K, Nakanuma Y. Nodular regenerative hyperplasia of the liver in hepatocellular carcinoma. An autopsy study. J Clin Gastroenterol 1993; 16:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/54\">",
"      Thung SN, Gerber MA. Enzyme pattern and marker antigens in nodular \"regenerative\" hyperplasia of the liver. Cancer 1981; 47:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/55\">",
"      Russmann S, Zimmermann A, Kr&auml;henb&uuml;hl S, et al. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol 2001; 13:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/56\">",
"      de Saint-Maur PP. [Regenerative nodular hyperplasia and hepatocarcinoma]. Ann Pathol 1988; 8:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/57\">",
"      Nguyen TD, Oakes D, Fogel MR, et al. Hepatocellular adenoma and nodular regenerative hyperplasia of the liver in a young man. J Clin Gastroenterol 1986; 8:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/58\">",
"      Bretagne JF, Deugnier Y, Launois B, et al. [Regenerative nodular hyperplasia, hepatocellular carcinoma and oral contraceptives]. Gastroenterol Clin Biol 1984; 8:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/59\">",
"      Stromeyer FW, Ishak KG. Nodular transformation (nodular \"regenerative\" hyperplasia) of the liver. A clinicopathologic study of 30 cases. Hum Pathol 1981; 12:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/60\">",
"      Gane E, Portmann B, Saxena R, et al. Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology 1994; 20:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/61\">",
"      Radomski JS, Chojnacki KA, Moritz MJ, et al. Results of liver transplantation for nodular regenerative hyperplasia. Am Surg 2000; 66:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/62\">",
"      Krishna M, Keaveny AP, Genco PV, et al. Clinicopathological review of 18 cases of liver allografts lost due to bile duct necrosis. Transplant Proc 2005; 37:2221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/63\">",
"      McDonald JA, Painter DM, Gallagher ND, McCaughan GW. Nodular regenerative hyperplasia mimicking cirrhosis of the liver. Gut 1990; 31:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/64\">",
"      Dumortier J, Bizollon T, Scoazec JY, et al. Orthotopic liver transplantation for idiopathic portal hypertension: indications and outcome. Scand J Gastroenterol 2001; 36:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37095/abstract/65\">",
"      Loinaz C, Colina F, Musella M, et al. Orthotopic liver transplantation in 4 patients with portal hypertension and non-cirrhotic nodular liver. Hepatogastroenterology 1998; 45:1787.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3601 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-122.72.80.101-2F8DE301F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_14_37095=[""].join("\n");
var outline_f36_14_37095=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LIVER PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3601\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3601|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/40/24195\" title=\"picture 1A\">",
"      Hepatic NRH light low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/56/16264\" title=\"picture 1B\">",
"      Hepatic NRH light high",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3601|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/27/26045\" title=\"table 1\">",
"      Diseases assoc with NRH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/35/34359?source=related_link\">",
"      Indications for the use of transjugular intrahepatic portosystemic shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/40/14985?source=related_link\">",
"      Noncirrhotic portal hypertension: Portal fibrosis and schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43526?source=related_link\">",
"      Ursodeoxycholic acid in the treatment of primary biliary cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_14_37096="Intraventricular conduction delay";
var content_f36_14_37096=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Intraventricular conduction delay",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 225px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The QRS duration is &gt;0.10 seconds, but the QRS morphology does not resemble a left or right bundle branch block.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_14_37096=[""].join("\n");
var outline_f36_14_37096=null;
var title_f36_14_37097="Factor XI deficiency";
var content_f36_14_37097=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Factor XI deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/14/37097/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/14/37097/contributors\">",
"     Caroline B&eacute;rub&eacute;, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/14/37097/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/14/37097/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/14/37097/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/14/37097/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/14/37097/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor XI (FXI) is a plasma glycoprotein that participates in the contact phase of blood coagulation (ie, the intrinsic pathway). Unlike the other contact factors (ie, high molecular weight kininogen, factor XII, prekallikrein), FXI is important for normal hemostasis in vivo. It plays an important role in the amplification of the initial coagulation response via a positive feedback mechanism for the generation of additional thrombin.",
"   </p>",
"   <p>",
"    The biology of FXI, its alterations in disease states, and treatment of the deficiency state will be discussed here. Overviews of blood coagulation and of rare, recessively inherited coagulation disorders are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16730?source=see_link\">",
"     \"Rare (recessively inherited) coagulation disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOLOGY OF FACTOR XI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human FXI is found in both plasma and platelets, although platelet FXI contributes less than 1 percent of total circulating FXI clotting activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/1\">",
"     1",
"    </a>",
"    ]. Plasma FXI circulates in complex with high molecular weight kininogen (HMWK). In the presence of zinc ions this complex binds to high affinity sites on the surface of activated platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/2\">",
"     2",
"    </a>",
"    ]. Prothrombin and calcium ions can substitute for the",
"    <span class=\"nowrap\">",
"     HMWK/zinc",
"    </span>",
"    complex, explaining why HMWK deficiency does not lead to a bleeding disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary site of FXI synthesis is the liver. Patients with liver disease may therefore have decreased levels of FXI. FXI activity is low at birth and correlates with gestational age; adult levels are reached by six months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/4\">",
"     4",
"    </a>",
"    ]. The source of platelet factor XI and its contribution to hemostasis are unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FXI is the zymogen for the active enzyme factor FXIa. Since FXIa is essential for propagation of the coagulation response, its regulation remains crucial. FXIa is regulated by two classes of inhibitors, serine protease inhibitors (serpins) and Kunitz-type inhibitors. The serpins shown to be involved in FXIa inhibition are antithrombin (AT), alpha-1 protease inhibitor, and C1 inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any FXIa that is not bound to platelets, is inhibited by protease nexin-2 (PN2) secreted by activated platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. However, binding of FXIa to the platelet surface protects it from inactivation by PN2, localizing production of thrombin to activated platelets at the site of initial injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Role in coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;During plasma clotting assays in vitro, FXI is activated by FXIIa on negatively charged surfaces, known as contact activation. The physiologic role of this activation step is unclear at the present time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although factor XI does not play an important role in the initiation of blood coagulation in vivo, it is essential for its propagation and maintenance. Normal hemostasis is initiated via the extrinsic pathway involving circulating factor VIIa and tissue factor, which together activate factor X (",
"    <a class=\"graphic graphic_algorithm graphicRef62974 \" href=\"mobipreview.htm?31/46/32494\">",
"     algorithm 1",
"    </a>",
"    ). Activated factor X (factor Xa) and V then convert prothrombin to thrombin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of hemostasis\", section on 'Thrombin generation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This pathway is rapidly inhibited by tissue factor pathway inhibitor (TFPI), such that only a small amount of thrombin is generated. Although this initial formation of thrombin is sufficient to generate fibrin from fibrinogen, the coagulation process is maintained and amplified only through the subsequent activation of platelets, as well as factors XI, VIII, and V by this initial burst of thrombin formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. This supplemental thrombin formation at the site of the clot is also critical for the activation of thrombin-activatable fibrinolysis inhibitor (TAFI), which stabilizes the clot by increasing its resistance to fibrinolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, FXI plays a dual role by both helping to generate additional thrombin and downregulating fibrinolysis. These observations provide an explanation as to why FXI deficient patients do not generally have spontaneous bleeding but are prone to bleeding provoked by trauma or surgery, particularly when tissues with high intrinsic fibrinolytic activity (eg, nose, oral cavity, tonsils, genitourinary tract) are involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Structure and function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factor XI gene is located on the long arm of chromosome 4 (4q34-35) and consists of 15 exons and 14 introns. It encodes a 607 amino acid protein with a number of distinctive structural and functional features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factor XI is unique among the coagulation factors in that it circulates in blood in zymogen form as a disulfide-linked homodimer in a noncovalent complex with high molecular weight kininogen (HMWK) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/2,21\">",
"     2,21",
"    </a>",
"    ]. Each identical 80 kD monomer can be activated following cleavage at Arg369-Ile370 by its activators, namely thrombin, factor XIIa, and by autoactivation by factor XIa itself, generating two chains. The light chain contains the catalytic site whereas the heavy chain contains the four tandem repeat sequences (Apple domains, A1 to A4). The Apple domains are not found in other coagulation proteases, with the exception of prekallikrein, and are responsible for substrate and ligand binding as well as the dimerization process itself, mediated through the A4 domain. Production of the homodimer is also essential for the secretion of factor XI from producing cells in the liver. Activated FXI remains in its dimeric form, which is also essential to its normal function of factor IX cleavage and activation.",
"   </p>",
"   <p>",
"    Mutations of the FXI gene leading to FXI deficiency can occur in the Apple domains or the catalytic site. One of the most common mutations in the Ashkenazi Jews is a missense mutation in the Apple 4 domain, which is important for FXI dimerization, resulting in low circulating levels of FXI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/22\">",
"     22",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H10\">",
"     'Jewish populations'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    FXI is the only coagulation protease, with the exception of FXII and prekallikrein, that does not contain \"Gla domains,\" sequences rich in gamma-carboxyglutamic acids that are required for binding to phospholipids. Despite the absence of Gla domains and its inability to bind to phospholipids, FXI and FXIa bind to activated platelets in a specific and saturable manner.",
"   </p>",
"   <p>",
"    Glycoprotein Ib is the platelet receptor for plasma FXI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/23\">",
"     23",
"    </a>",
"    ]. FXI binds to the glycoprotein Ib-IX-V complex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The non-covalent complexing of HMWK (or prothrombin) to FXI is required for the exposure of the binding site on the A3 domain of FXI to allow its binding to glycoprotein Ib alpha (GPIb alpha) on activated platelets. The FXI homodimer binds to GPIb alpha through one of its monomers, leaving the second one free for activation by thrombin, which also binds to the platelet surface GPIb alpha via its exosite II. This provides the proper orientation of thrombin, such that the exosite I and active site of thrombin are properly aligned for their interaction with and activation of FXI. In this model, GPIb alpha plays an important role in co-localizing thrombin and FXI to form a quaternary complex on the activated platelet surface, allowing for the activation of FXI by its physiologic activator (thrombin) on the surface of the activated platelet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     FACTOR XI MUTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor XI deficiency may result from impaired protein production or secretion, dimerization, or by a mechanism of heterodimer trapping in heterozygous subjects.",
"   </p>",
"   <p>",
"    Most of the molecular and clinical data concerning FXI deficiency have come from population studies among Jewish patients. The first three mutations of the FXI gene (designated types I to III) were reported in 1989 in six Ashkenazi Jewish patients who had severe factor XI deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/25\">",
"     25",
"    </a>",
"    ]. A Type IV mutation was reported in 1991 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/26\">",
"     26",
"    </a>",
"    ]. The type II mutation (E117X) causes a premature chain termination and results in very low levels of circulating FXI, whereas the Type III mutation (F283L) results in impaired dimerization and secretion of the FXI molecule. Both type II and type III point mutations are highly prevalent and occur at approximately equal frequency, whereas types I and IV are rare. Thus, nearly all Ashkenazi Jewish individuals with severe factor XI deficiency have either the",
"    <span class=\"nowrap\">",
"     II/II,",
"    </span>",
"    <span class=\"nowrap\">",
"     III/III,",
"    </span>",
"    or compound heterozygous (ie,",
"    <span class=\"nowrap\">",
"     II/III)",
"    </span>",
"    genotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the bleeding risk appears to be increased in all genotypes when tissues with high fibrinolytic activity are involved, there is a correlation between these genotypes and the level of FXI coagulant activity. A study in Israel of 43 patients with severe FXI deficiency found factor XI levels of 1.2 percent, 3.3 percent and 9.7 percent for genotypes",
"    <span class=\"nowrap\">",
"     II/II,",
"    </span>",
"    <span class=\"nowrap\">",
"     II/III,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     III/III,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some mutations can cause a moderate to severe FXI deficiency by producing aberrant proteins exerting a pattern of dominant transmission through formation of heterodimers between the mutant and wild-type proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Apparently, these heterodimers are formed intracellularly but are not secretable, leading to a more significant reduction in plasma FXI levels (eg, approximately 20 percent) than usually encountered in patients with heterozygous autosomal recessive FXI deficiency. With rare exceptions, factor XI mutations result in decreased factor XI protein proportionate to the decrease in factor XI clotting activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 190 FXI mutations have been identified to date, affecting both the catalytic and Apple domains. A partial list of these mutations can be found in the International Society of Thrombosis and Haemostasis database of mutations causing rare bleeding disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/33\">",
"     33",
"    </a>",
"    ]. A comprehensive web-based database and useful links of reported FXI mutations with genotypic and phenotypic information is also available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Combined coagulation deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coinheritance of factor XI deficiency along with another congenital coagulation disorder has been observed on rare occasions. This has included patients with Von Willebrand disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/36-38\">",
"     36-38",
"    </a>",
"    ], factor VII deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/39\">",
"     39",
"    </a>",
"    ], and hemophilia A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormal bleeding in patients with Noonan syndrome has been associated with a number of alterations in platelet function as well as coagulation factors, including a mild deficiency of factor XI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The mechanism for such abnormalities is unknown, since the defective gene for Noonan syndrome is on chromosome 12, whereas the factor XI gene is situated on chromosome 4. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/62/39910?source=see_link\">",
"     \"Clinical manifestations and diagnosis of pulmonic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INHERITED FACTOR XI DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor XI deficiency (Rosenthal syndrome, hemophilia C) is an autosomal disorder affecting both men and women, which results in a bleeding disorder of variable severity. It is not truly a recessive disorder, since some heterozygotes may have mild bleeding, while other FXI mutations may lead to an autosomal dominant disease pattern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     General population",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor XI deficiency is uncommon among the non-Jewish population and consists mostly of sporadic cases, with an estimated incidence of one case per million population. However, clusters of subjects with factor XI deficiency have been identified among non-Jewish individuals. A common ancestral mutation (C128X) was reported in 11 non-Jewish families from the UK [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/44\">",
"     44",
"    </a>",
"    ]. In France, two mutations were identified. One is a mutation (C38R) in exon 3, reported in 8 of 12 families with FXI deficiency in French Basques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/45\">",
"     45",
"    </a>",
"    ]. The second one is an ancient mutation in exon 4 (Q88X) in individuals from Nantes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Jewish populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital FXI deficiency is common among Ashkenazi Jews, with a rate of heterozygosity as high as 8 to 9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/47\">",
"     47",
"    </a>",
"    ]. Estimates of homozygosity for FXI deficiency among Ashkenazi Jews have varied from 0.22 to 0.53 percent, making congenital FXI deficiency one of the most prevalent genetic defects in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other Jewish populations have been screened for mutations of FXI. The type II mutation (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Factor XI mutations'",
"    </a>",
"    above) is present among Sephardic and Iraqi Jews. Among Iraqi Jews, the heterozygosity rate was found to be 3.3 percent and the risk of homozygosity 0.03 percent, while the type III mutation has not been found in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/47\">",
"     47",
"    </a>",
"    ]. This observation suggests that the type II mutation occurred in ancient times while the type III mutation appeared in more recent times.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ACQUIRED FACTOR XI DEFICIENCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25453942\">",
"    <span class=\"h2\">",
"     Decreased production or increased consumption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired factor XI deficiency is mainly observed in patients with liver disease, due to failure of production, or following the onset of disseminated intravascular coagulation, due to increased activation and consumption. Acquired FXI deficiency has also been reported following liver transplantation from a FXI-deficient donor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     FXI inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;FXI inhibitors are rare and have been reported in patients with severe congenital FXI deficiency following plasma infusion or in autoimmune diseases such as systemic lupus erythematosus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24650?source=see_link&amp;anchor=H29#H29\">",
"     \"Acquired inhibitors of coagulation\", section on 'Factor XI inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An inhibitor to FXI is usually detected in patients either during preoperative screening, following failure to achieve a significant rise of FXI activity after infusion of plasma or FXI concentrates, or in patients with known FXI deficiency who have a worsening bleeding pattern. Most patients with FXI inhibitors do not bleed spontaneously but can bleed seriously during or after trauma or surgery.",
"   </p>",
"   <p>",
"    The likelihood of developing a FXI inhibitor is particularly high among individuals with extremely low levels of plasma factor XI who are subsequently exposed to plasma-derived FXI. One study of 118 unrelated individuals with severe congenital FXI deficiency found seven patients who had developed inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/51\">",
"     51",
"    </a>",
"    ]. All seven were homozygous for a type II mutation with FXI levels &le;1 percent, and had received plasma replacement therapy. The incidence of an inhibitor among the 21 type II homozygotes who had been previously exposed to plasma infusion was 33 percent. Inhibitors did not develop in untransfused type II homozygotes, or in those with other factor XI mutations. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Factor XI mutations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An Rh negative patient homozygous for the type II mutation developed a factor XI inhibitor following use of Rh immune globulin during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/52\">",
"     52",
"    </a>",
"    ]. Analysis of batches of Rh immune globulin revealed the presence of factor XI in preparations from three different suppliers, in concentrations ranging from 20 nanograms to 6.5 micrograms per recommended dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bleeding manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical phenotype of FXI deficiency is heterogeneous and the bleeding risk is variable within an individual in response to different hemostatic challenges. There is also a poor correlation between the degree of plasma FXI deficiency and the bleeding tendency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/53\">",
"     53",
"    </a>",
"    ]. Two studies have suggested that this variability may be explained by differences in thrombin generation, as measured by in vitro thrombin generation or by thromboelastography (TEG), research tests not widely available at the present time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/54-56\">",
"     54-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike classic hemophilia A or B, most patients with severe FXI deficiency (ie, FXI activity &lt;15 percent) do not suffer from spontaneous bleeding but are at risk of bleeding following trauma or surgery. Hemarthrosis and muscle hematomas, common in hemophilia A or B, are not typically observed in FXI deficient patients. Occasional symptoms of FXI deficiency also include easy bruising and epistaxis.",
"   </p>",
"   <p>",
"    A retrospective analysis was performed of bleeding complications in 120 patients with severe FXI deficiency who had undergone surgical procedures without replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/57\">",
"     57",
"    </a>",
"    ]. Procedures performed on tissues exhibiting fibrinolytic activity were associated with bleeding in 49 to 67 percent, while those involving sites with no local fibrinolytic activity were associated with bleeding in 1.5 to 40 percent. The incidence of bleeding following circumcision was 1.5 percent.",
"   </p>",
"   <p>",
"    The bleeding risk in patients with heterozygous FXI deficiency is significantly lower than that in homozygous or compound heterozygous patients. However, 20 to 50 percent of patients with partial FXI deficiency bleed excessively after surgical challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/30,58\">",
"     30,58",
"    </a>",
"    ]. Such patients cannot be easily identified in advance, although the additional presence of platelet dysfunction or low von Willebrand Factor levels may play a role in modulation of the bleeding risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/36\">",
"     36",
"    </a>",
"    ]. Ingestion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and nonsteroidal antiinflammatory drugs has been identified as a risk factor for bleeding in patients with heterozygous FXI deficiency, and should be avoided whenever possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bleeding tendency in FXI deficiency is influenced by both the site of surgery and the genotype. Surgical procedures involving tissues with high fibrinolytic activity (eg, dental extractions, tonsillectomy, nasal and prostatic surgery) enhance the bleeding risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/57\">",
"     57",
"    </a>",
"    ]. Bleeding after circumcision is uncommon, although absence of bleeding following circumcision does not rule out the diagnosis of FXI deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Menses and pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with FXI deficiency are more likely to have menorrhagia and postpartum hemorrhage (PPH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/60\">",
"     60",
"    </a>",
"    ], although the risk of PPH in affected women is quite variable and may have no relationship with the abnormal genotype that caused factor XI deficiency, nor with their factor XI level or the bleeding history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. In one study, levels of factor XI taken during the third trimester were not significantly different from those obtained pre-pregnancy, both for those with severe, as well as those with partial, deficiencies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The variability of PPH in these patients was illustrated in a study of pregnancy outcome in 62 women with severe factor XI deficiency (&lt;17",
"    <span class=\"nowrap\">",
"     U/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      43 of the women (69 percent) never experienced PPH during 93 deliveries (85 vaginal, eight cesarean)",
"     </li>",
"     <li>",
"      PPH occurred in 19 women, and in six women accompanied each one of their 17 vaginal deliveries",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a second retrospective analysis, 33 women with factor XI deficiency (30 partial, three severe, of non-Jewish descent) were characterized as having a \"bleeding\" (16 women) or \"nonbleeding\" (17 women) phenotype (ie, combined personal history of bruising tendency, epistaxis, GI bleeding, hematuria, excess menstrual bleeding needing treatment, bleeding post surgery or dental extraction, bleeding in relation to pregnancy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/29\">",
"     29",
"    </a>",
"    ]. In the absence of prophylactic FXI replacement, the outcome of 105 pregnancies in these 33 women included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/63\">",
"     63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy and delivery were uncomplicated in 76 and 65 percent of the \"nonbleeders\" and \"bleeders\", respectively. Of those pregnancies resulting in a live birth, these percentages were 92 and 72 percent, respectively.",
"     </li>",
"     <li>",
"      There were nine episodes of PPH; all but one episode occurred in the women considered to be \"bleeders\" (relative risk of PPH for \"bleeders\" versus &ldquo;nonbleeders&rdquo; 7.2; 95% CI 2-26).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on the above observations, the overall risk of PPH in severely affected patients ranges from 17 to 30 percent in the absence of routine replacement therapy during labor; no PPH episode was fatal. Bleeding risk does not appear to be greater with Cesarean section, although the number of reported cases is too small to draw definite conclusions. In a second study, which included 61 pregnancies among 30 women with factor XI deficiency, all of the women who experienced excessive bleeding due to pregnancy loss or antepartum bleeding and four of the seven with PPH had a \"bleeder\" phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     LABORATORY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal levels of FXI activity range from 70 to 150 percent (70 to 150",
"    <span class=\"nowrap\">",
"     U/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/58\">",
"     58",
"    </a>",
"    ]. Congenital deficiencies as the result of a mutation in the FXI gene are defined as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe deficiency (FXI activity &lt;15 percent) &mdash; This category includes individuals who are homozygotes or compound heterozygotes for a causative mutation of FXI.",
"     </li>",
"     <li>",
"      Partial deficiency (FXI activity 20 to 70 percent) &mdash; This category includes individuals who are heterozygous for a FXI mutation. Occasional heterozygotes may have FXI levels within the normal range.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Individuals homozygous for FXI deficiency have severely reduced FXI activity, usually &lt;15 percent of normal. In such patients the activated partial thromboplastin time (aPTT) is prolonged, whereas the prothrombin and thrombin times are normal. If plasma from a patient with congenital FXI deficiency is mixed with normal pooled plasma in a ratio of 1:1, this should correct the prolonged aPTT. If the aPTT is not corrected by this maneuver, presence of an inhibitor to FXI should be suspected, although the presence of other inhibitors (eg, lupus anticoagulant,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , factor VIII or factor IX antibodies) must also be ruled out. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical use of coagulation tests\", section on 'Mixing studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals with partial FXI deficiency (ie, heterozygotes) usually have FXI activity between 20 and 70 percent of normal. Those in the higher activity range can have a normal aPTT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10520694\">",
"    <span class=\"h2\">",
"     Making the diagnosis of FXI deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of severe congenital FXI deficiency is straightforward, and consists of the following elements:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A prolonged aPTT, with normal prothrombin and thrombin times",
"     </li>",
"     <li>",
"      FXI activity &lt;15 percent of normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of a partial deficiency of FXI (ie, FXI activity 20 to 70 percent of normal) is less straightforward, since these patients may have FXI activity close to the lower limit of normal along with a normal aPTT. Molecular testing for the presence of a factor XI mutation is the only definitive test in individuals with borderline FXI activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10520702\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of subjects with a prolonged aPTT and normal prothrombin and thrombin times includes the following disorders (",
"    <a class=\"graphic graphic_table graphicRef79969 \" href=\"mobipreview.htm?42/45/43740\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical use of coagulation tests\", section on 'Causes of prolonged aPTT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Deficiency of coagulation factors VIII or IX, or von Willebrand disease (associated with bleeding)",
"     </li>",
"     <li>",
"      Deficiency of coagulation factors XII, prekallikrein, or HMW kininogen (not associated with bleeding)",
"     </li>",
"     <li>",
"      Presence of a lupus anticoagulant (associated with thrombosis rather than bleeding)",
"     </li>",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or heparin in the blood sample being tested",
"     </li>",
"     <li>",
"      Acquired inhibitors of factors VIII, IX, or XII or acquired von Willebrand disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific assays are available for making these diagnoses; FXI activity will be normal in all, with the exception of lupus anticoagulant where moderate deficiency of multiple clotting factors, including factors XI, IX, VIII and X will be found.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with factor XI (FXI) deficiency do not need prophylaxis for routine daily activity but may need treatment for dental extraction, major surgery, or trauma. Surgery or injury involving tissues with high fibrinolytic activity are definitely associated with higher bleeding risk (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Bleeding manifestations'",
"    </a>",
"    above). Of importance, antiplatelet agents,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , and other NSAIDs are absolutely contraindicated before surgery, as their presence may increase the risk of bleeding. At other times, these agents are relatively contraindicated.",
"   </p>",
"   <p>",
"    Treatment is determined by the type of intervention planned, the level of FXI activity of the individual patient, and the clinical history of bleeding. Screening for the presence of a FXI inhibitor should be part of the preoperative evaluation, especially in severely deficient individuals with a type II mutation (see",
"    <a class=\"local\" href=\"#H13\">",
"     'FXI inhibitors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H20\">",
"     'Laboratory testing'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a single case report of a patient with factor XI deficiency, hepatitis C virus-associated cirrhosis, and hepatocellular carcinoma, whose factor XI deficiency was corrected after liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10520752\">",
"    <span class=\"h2\">",
"     Labor and delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision for prophylactic therapy during labor and delivery needs to be individualized according to baseline FXI level, bleeding history, and mode of delivery. The suggested management of women with FXI deficiency at the time of delivery is as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/20,61,62\">",
"     20,61,62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women with partial factor XI deficiency and in the absence of a positive bleeding history, no routine replacement therapy is warranted prior to vaginal delivery, and a \"watch and wait\" approach with replacement therapy when bleeding occurs is suggested. Prophylactic treatment with a short course of oral antifibrinolytic agents is advisable in women without prior hemostatic challenge to reduce the risk of postpartum blood loss.",
"     </li>",
"     <li>",
"      In women with partial FXI deficiency and previous bleeding history, prophylactic therapy with antifibrinolytic agents is recommended for three to five days after vaginal delivery. Replacement therapy can be administered &ldquo;on demand&rdquo; if there is excessive bleeding.",
"     </li>",
"     <li>",
"      There is no consensus on the routine need for replacement therapy in patients with severe FXI deficiency and vaginal delivery. Recommendations range from expectant management to replacement therapy. However, replacement therapy with fresh frozen plasma (15 to 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per day for two to four days) or FXI concentrates (see below) starting during labor should be considered in all women with severe FXI deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/65\">",
"       65",
"      </a>",
"      ], and should definitely be used in women with a significant bleeding phenotype, as previous bleeding history predicts postpartum hemorrhage. Oral antifibrinolytic agents for up to two weeks are advisable to reduce postpartum bleeding. The concomitant use of antifibrinolytic agents and FXI concentrates should be avoided as their combination may be prothrombotic.",
"     </li>",
"     <li>",
"      The safety of a \"watch and wait\" approach in the setting of Cesarean section has not been validated, and routine replacement therapy, although controversial, is used more frequently.",
"     </li>",
"     <li>",
"      Epidural anesthesia has been performed without complications in a small number of women prior to their diagnosis of FXI deficiency. However, given the potential risk for spinal hematoma, epidural anesthesia can only be recommended following replacement therapy with an appropriate hemostatic response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10520743\">",
"    <span class=\"h1\">",
"     AVAILABLE TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available therapeutic modalities include antifibrinolytic agents, fibrin sealant (fibrin glue), fresh frozen plasma, factor XI concentrates (not available in the United States),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (dDAVP), and recombinant human activated factor VII. These are discussed below, along with indications for their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Antifibrinolytic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antifibrinolytic agents alone or as an adjuvant to replacement therapy have been used extensively in FXI deficiency to prevent bleeding in tissues with high fibrinolytic activity, such as the oropharynx and prostate. Antifibrinolytic therapy alone has also been used in the treatment of women with FXI deficiency and menorrhagia.",
"   </p>",
"   <p>",
"    Dental extraction, which is associated with significant bleeding risk in patients with mild or severe FXI deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/29\">",
"     29",
"    </a>",
"    ], can be safely performed using antifibrinolytic agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    or epsilon-aminocaproic acid (EACA, Amicar) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/66-68\">",
"     66-68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"       Tranexamic acid",
"      </a>",
"      can be used as a 5 percent mouthwash or tablets in an oral dose of 1 g or 25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (not readily available in the United States), or intravenously in a dose of 10",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      Doses should be repeated every six to eight hours for a total of seven days, starting 12 hours before surgery.",
"     </li>",
"     <li>",
"      Alternatively, EACA can be used as an oral rinse (15 mL of a solution or syrup containing 1.25",
"      <span class=\"nowrap\">",
"       g/5",
"      </span>",
"      mL) for two minutes, or an oral dose of 50 to 60",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      repeated every four to six hours (off-label use). Replacement therapy is not required [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     FXI replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;FXI replacement therapy is warranted for surgical prophylaxis or treatment of symptomatic bleeding. This is usually achieved by raising the factor XI level to achieve a nadir or trough level of 30 to 45 percent of normal activity. The recovery of infused FXI in the plasma following infusion is around 90 percent and the half-life of transfused FXI is estimated to be between 50 to 80 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/69\">",
"     69",
"    </a>",
"    ]. These characteristics facilitate the postoperative replacement therapy. For major surgeries, the replacement must start before surgery and last approximately five to seven days. There is no need for replacement therapy for minor procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Fresh-frozen plasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusion of fresh frozen plasma is effective in raising FXI levels, but requires the use of large amounts of plasma and carries the potential risk of fluid overload, blood-borne infection, and allergic reactions. A loading dose of 10 to 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    can be followed by 5 to 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    daily. Use of solvent-detergent frozen plasma reduces the exposure to lipid-enveloped viruses but at a substantially higher cost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     FXI concentrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma-derived high purity FXI concentrates that are virally inactivated are not currently available in the United States, but are available in the United Kingdom (FXI concentrate, BioProducts Laboratory) and France (Hemoleven",
"    <sup>",
"     &reg;",
"    </sup>",
"    , LFB). They are very effective and easy to administer rapidly, achieving a FXI increase of 1.8 percent for every",
"    <span class=\"nowrap\">",
"     unit/kg",
"    </span>",
"    given, and with a half-life of approximately 62 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/70\">",
"     70",
"    </a>",
"    ]. However, a number of side effects, including disseminated intravascular coagulation and arterial thrombosis have been reported in about 10 percent of patients receiving these preparations. These complications are particularly common in older patients with preexisting risk factors for thrombosis or in those receiving &gt;50",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    of factor XI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/71-73\">",
"     71-73",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    and antithrombin are now added during the manufacturing process of these concentrates in order to reduce these risks.",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration offers a mechanism to facilitate limited use of replacement products licensed abroad, through the use of an investigator-initiated Institutional Review Board (IRB)-approved protocol. This may be considered in patients unable to receive plasma infusion for correction of their FXI deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Desmopressin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few case series suggest that use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (dDAVP) at a dose of 0.3",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    SQ or IV could prevent clinical bleeding when used for surgery in heterozygous FXI deficient patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. However, the efficacy of dDAVP in this setting remains unclear, as many patients also received concurrent treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    . In a few case series, for example, FXI coagulable activity and antigen levels were only minimally increased following dDAVP infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/74-76\">",
"     74-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second report evaluated the level of FXI achieved following dDAVP infusion in 33 patients with type 1 Von Willebrand disease or mild hemophilia A, and failed to show any increase in FXI levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/77\">",
"     77",
"    </a>",
"    ]. It is possible that the efficacy of dDAVP, if any, is mediated through higher plasma concentrations of both factor VIII and Von Willebrand factor, supporting hemostasis and platelet adhesion in a factor XI-independent manner. The true benefit of dDAVP is unclear; use of this agent should be restricted to a selected group of heterozygous patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Recombinant factor VIIa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case reports suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    (rhFVIIa), when given along with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    , is effective for the treatment of patients with FXI deficiency undergoing surgery, including those with inhibitors as well as in those requiring regional anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/55,67,68,78-81\">",
"     55,67,68,78-81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=see_link\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of rhFVIIa in this setting avoids exposure to human plasma, which may be clinically relevant in patients with severe FXI deficiency, especially those homozygous for the type II mutation, who are most prone to develop a FXI inhibitor after plasma infusion. Thrombotic complications have been reported in elderly patients with preexisting hypercoagulable states who have received treatment with this product. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'FXI inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The optimal dose regimen for patients with FXI deficiency is unknown and requires additional clinical data. In one pilot study, 15 procedures were performed in 14 FXI-deficient patients (initial dose 90",
"    <span class=\"nowrap\">",
"     microg/kg)",
"    </span>",
"    without any evidence of bleeding and without the need for additional hemostatic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/67\">",
"     67",
"    </a>",
"    ]. Adverse events included one allergic reaction, one episode of a mild local phlebitis, and one fatal cerebrovascular infarction after 48 hours of treatment with rhFVIIa.",
"   </p>",
"   <p>",
"    Concerns over the risk of thrombosis have led to the development of a regimen using very low dose rhFVIIa, supported by in vitro data showing satisfactory thrombin generation following low dose rhFVIIa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/68\">",
"     68",
"    </a>",
"    ]. In one report, three patients with FXI inhibitors and one with IgA deficiency were treated perioperatively using a single low dose rhFVIIa of 15 to 30",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    2 g pre-op and 1 g every six hours for 7 to 14 days. No excessive bleeding or thrombosis was observed in four treated patients undergoing five surgeries (two laparoscopic cholecystectomies, one transurethral prostatectomy, one parotidectomy, one transurethral resection of tumor of bladder). None of the patients required blood transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A low dose of rhFVIIa (20",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    bolus, followed by continuous infusion at 1.8 to 3.6",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    per hour) was found to be safe and highly effective in the management of one patient undergoing laminectomy on two separate occasions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/82\">",
"     82",
"    </a>",
"    ]. Similarly, one single dose of 12",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    was highly effective in the management of post partum hemorrhage in one patient with severe FXI deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/83\">",
"     83",
"    </a>",
"    ]. Such lower doses of this agent may also be associated with less thrombotic risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, much lower doses of rhFVIIa than used in hemophiliacs with inhibitors appear to be effective in individuals with factor XI deficiency, with or without inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10520425\">",
"    <span class=\"h1\">",
"     POSSIBLE PROTECTIVE EFFECTS OF FACTOR XI DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;High levels of FXI have been shown to be a risk factor for thrombosis. In a case-control study from the Leiden Thrombophilia Study, high levels of FXI (ie, &gt;90th percentile) were associated with a doubling of the risk of developing deep venous thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/84\">",
"     84",
"    </a>",
"    ]. This observation was confirmed in a second large case-control study showing an odds ratio of 1.8 (95% CI 1.3-2.7) after adjustment for other factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/85\">",
"     85",
"    </a>",
"    ]. The Austrian Study on Recurrent Venous Thromboembolism (AUREC), a cohort study, found that subjects with high levels of TAFI, in association with higher levels of factors VIII, IX and XI, had an increased risk of recurrent venous thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/86\">",
"     86",
"    </a>",
"    ]. In addition, high levels of FXI have been associated with an increased risk of ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Elevated clotting factors and chemokines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since increased levels of FXI increase thrombotic risk, FXI deficiency might act to reduce thrombotic risk via a combination of decreased thrombin generation and increased fibrinolysis (",
"    <a class=\"graphic graphic_algorithm graphicRef62974 \" href=\"mobipreview.htm?31/46/32494\">",
"     algorithm 1",
"    </a>",
"    ). This has been shown in animal models, in which factor XI deficiency exerts an antithrombotic effect in both venous and arterial models of thrombosis. Israeli studies in patients with severe FXI deficiency have suggested that FXI deficiency has a protective effect against deep vein thrombosis and stroke but not against myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/14/37097/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10226536\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Factor XI deficiency is an autosomal recessive bleeding disorder common among Ashkenazi Jews. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Inherited factor XI deficiency'",
"      </a>",
"      above.) Coagulation factor XI (FXI) plays an important role in the amplification of the initial coagulation response via a positive feedback mechanism for the generation of additional thrombin (",
"      <a class=\"graphic graphic_algorithm graphicRef62974 \" href=\"mobipreview.htm?31/46/32494\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Biology of factor XI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with severe FXI deficiency (ie, activity &lt;15 percent), the activated partial thromboplastin time (aPTT) is prolonged, whereas the prothrombin time (PT), thrombin time (TT), and bleeding times (BT) are normal. Depending upon reagent sensitivity, patients with partial FXI deficiency may have a normal aPTT. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical phenotype of severe FXI deficiency is heterogeneous, with a poor correlation between plasma FXI levels and bleeding. Most do not suffer from spontaneous bleeding but are at risk of bleeding following trauma or surgery, and are at higher, variable risk for menorrhagia and postpartum hemorrhage. Twenty to 50 percent of patients with partial FXI deficiency bleed excessively after surgical challenge. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Bleeding manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with FXI deficiency do not need prophylaxis for routine daily activity. Prophylaxis is similarly not necessary for some patients with severe deficiency undergoing minor procedures, and for most patients with partial FXI deficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest use of antifibrinolytic agents alone, rather than no therapy or use of factor XI replacement, for those undergoing routine dental surgery as well as for women with excessive menstrual bleeding (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Antifibrinolytic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the use of FXI replacement therapy with fresh frozen plasma or FXI concentrates for surgical prophylaxis, especially for surgery in areas of high fibrinolytic activity (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ), or for treatment of symptomatic bleeding (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This is usually achieved by raising the factor XI level to achieve a trough level of 30 to 45 percent, starting before surgery and lasting five to seven days. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'FXI replacement therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the routine use of factor XI replacement during vaginal delivery only in those with a &ldquo;bleeding phenotype&rdquo;",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe FXI deficiency (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest the use of antifibrinolytic agents in most patients to prevent post-partum hemorrhage, with the exception of those who have already received factor XI replacement, as the combination of these two agents may be prothrombotic (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Menses and pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/1\">",
"      Tuszynski GP, Bevacqua SJ, Schmaier AH, et al. Factor XI antigen and activity in human platelets. Blood 1982; 59:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/2\">",
"      von dem Borne PA, Koppelman SJ, Bouma BN, Meijers JC. Surface independent factor XI activation by thrombin in the presence of high molecular weight kininogen. Thromb Haemost 1994; 72:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/3\">",
"      Ho DH, Badellino K, Baglia FA, et al. The role of high molecular weight kininogen and prothrombin as cofactors in the binding of factor XI A3 domain to the platelet surface. J Biol Chem 2000; 275:25139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/4\">",
"      Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/5\">",
"      Podmore A, Smith M, Savidge G, Alhaq A. Real-time quantitative PCR analysis of factor XI mRNA variants in human platelets. J Thromb Haemost 2004; 2:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/6\">",
"      Gailani D, Zivelin A, Sinha D, Walsh PN. Do platelets synthesize factor XI? J Thromb Haemost 2004; 2:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/7\">",
"      Soons H, Janssen-Claessen T, Tans G, Hemker HC. Inhibition of factor XIa by antithrombin III. Biochemistry 1987; 26:4624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/8\">",
"      Walsh PN, Sinha D, Kueppers F, et al. Regulation of factor XIa activity by platelets and alpha 1-protease inhibitor. J Clin Invest 1987; 80:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/9\">",
"      Meijers JC, Vlooswijk RA, Bouma BN. Inhibition of human blood coagulation factor XIa by C-1 inhibitor. Biochemistry 1988; 27:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/10\">",
"      Saito H, Goldsmith GH, Moroi M, Aoki N. Inhibitory spectrum of alpha 2-plasmin inhibitor. Proc Natl Acad Sci U S A 1979; 76:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/11\">",
"      Van Nostrand WE, Schmaier AH, Farrow JS, Cunningham DD. Protease nexin-II (amyloid beta-protein precursor): a platelet alpha-granule protein. Science 1990; 248:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/12\">",
"      Smith RP, Higuchi DA, Broze GJ Jr. Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science 1990; 248:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/13\">",
"      Badellino KO, Walsh PN. Protease nexin II interactions with coagulation factor XIa are contained within the Kunitz protease inhibitor domain of protease nexin II and the factor XIa catalytic domain. Biochemistry 2000; 39:4769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/14\">",
"      Walsh PN. Roles of platelets and factor XI in the initiation of blood coagulation by thrombin. Thromb Haemost 2001; 86:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/15\">",
"      Pedicord DL, Seiffert D, Blat Y. Feedback activation of factor XI by thrombin does not occur in plasma. Proc Natl Acad Sci U S A 2007; 104:12855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/16\">",
"      Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science 1991; 253:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/17\">",
"      Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266:7353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/18\">",
"      Von dem Borne PA, Bajzar L, Meijers JC, et al. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/19\">",
"      Bouma BN, Meijers JC. Role of blood coagulation factor XI in downregulation of fibrinolysis. Curr Opin Hematol 2000; 7:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/20\">",
"      Bolton-Maggs PH. Factor XI deficiency--resolving the enigma? Hematology Am Soc Hematol Educ Program 2009; :97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/21\">",
"      Thompson RE, Mandle R Jr, Kaplan AP. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 1977; 60:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/22\">",
"      Meijers JC, Davie EW, Chung DW. Expression of human blood coagulation factor XI: characterization of the defect in factor XI type III deficiency. Blood 1992; 79:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/23\">",
"      Baglia FA, Shrimpton CN, L&oacute;pez JA, Walsh PN. The glycoprotein Ib-IX-V complex mediates localization of factor XI to lipid rafts on the platelet membrane. J Biol Chem 2003; 278:21744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/24\">",
"      Gailani D, Ho D, Sun MF, et al. Model for a factor IX activation complex on blood platelets: dimeric conformation of factor XIa is essential. Blood 2001; 97:3117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/25\">",
"      Asakai R, Chung DW, Ratnoff OD, Davie EW. Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations. Proc Natl Acad Sci U S A 1989; 86:7667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/26\">",
"      Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med 1991; 325:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/27\">",
"      Kravtsov DV, Wu W, Meijers JC, et al. Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. Blood 2004; 104:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/28\">",
"      Kravtsov DV, Monahan PE, Gailani D. A classification system for cross-reactive material-negative factor XI deficiency. Blood 2005; 105:4671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/29\">",
"      Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG. Definition of the bleeding tendency in factor XI-deficient kindreds--a clinical and laboratory study. Thromb Haemost 1995; 73:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/30\">",
"      Ragni MV, Sinha D, Seaman F, et al. Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds. Blood 1985; 65:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/31\">",
"      Abrahamian A, Xi MS, Donnelly JJ, Rockey JH. Effect of interferon-gamma on the expression of transforming growth factor-beta by human corneal fibroblasts: role in corneal immunoseclusion. J Interferon Cytokine Res 1995; 15:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/32\">",
"      Saito H, Ratnoff OD, Bouma BN, Seligsohn U. Failure to detect variant (CRM+) plasma thromboplastin antecedent (factor XI) molecules in hereditary plasma thromboplastin antecedent deficiency: a study of 125 patients of several ethnic backgrounds. J Lab Clin Med 1985; 106:718.",
"     </a>",
"    </li>",
"    <li>",
"     Search under Registries/Databases and then under Rare Bleeding Disorders at file://www.med.unc.edu/isth (Accessed on February 19, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/34\">",
"      Saunders RE, O'Connell NM, Lee CA, et al. Factor XI deficiency database: an interactive web database of mutations, phenotypes, and structural analysis tools. Hum Mutat 2005; 26:192.",
"     </a>",
"    </li>",
"    <li>",
"     www.factorxi.org (Accessed on February 19, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/36\">",
"      Tavori S, Brenner B, Tatarsky I. The effect of combined factor XI deficiency with von Willebrand factor abnormalities on haemorrhagic diathesis. Thromb Haemost 1990; 63:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/37\">",
"      Sano M, Saito H, Shimamoto Y, et al. Combined hereditary factor XI (plasma thromboplastin antecedent) deficiency, von Willebrand's disease, and xeroderma pigmentosum in a Japanese family. Am J Hematol 1993; 44:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/38\">",
"      Santoro R, Prejan&ograve; S, Iannaccaro P. Factor XI deficiency: a description of 34 cases and literature review. Blood Coagul Fibrinolysis 2011; 22:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/39\">",
"      B&eacute;rub&eacute; C, Ofosu FA, Kelton JG, Blajchman MA. A novel congenital haemostatic defect: combined factor VII and factor XI deficiency. Blood Coagul Fibrinolysis 1992; 3:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/40\">",
"      Berg LP, Varon D, Martinowitz U, et al. Combined factor VIII/factor XI deficiency may cause intra-familial clinical variability in haemophilia A among Ashkenazi Jews. Blood Coagul Fibrinolysis 1994; 5:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/41\">",
"      De Angelis V, Orazi BM, Santarossa L, Molaro G. Combined factor VIII and factor XI congenital deficiency: a case report. Haematologica 1990; 75:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/42\">",
"      Sharland M, Patton MA, Talbot S, et al. Coagulation-factor deficiencies and abnormal bleeding in Noonan's syndrome. Lancet 1992; 339:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/43\">",
"      Bertola DR, Carneiro JD, D'Amico EA, et al. Hematological findings in Noonan syndrome. Rev Hosp Clin Fac Med Sao Paulo 2003; 58:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/44\">",
"      Bolton-Maggs PH, Peretz H, Butler R, et al. A common ancestral mutation (C128X) occurring in 11 non-Jewish families from the UK with factor XI deficiency. J Thromb Haemost 2004; 2:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/45\">",
"      Zivelin A, Bauduer F, Ducout L, et al. Factor XI deficiency in French Basques is caused predominantly by an ancestral Cys38Arg mutation in the factor XI gene. Blood 2002; 99:2448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/46\">",
"      Mitchell M, Mountford R, Butler R, et al. Spectrum of factor XI (F11) mutations in the UK population--116 index cases and 140 mutations. Hum Mutat 2006; 27:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/47\">",
"      Shpilberg O, Peretz H, Zivelin A, et al. One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. Blood 1995; 85:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/48\">",
"      Seligsohn U. High gene frequency of factor XI (PTA) deficiency in Ashkenazi Jews. Blood 1978; 51:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/49\">",
"      Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. N Engl J Med 2001; 344:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/50\">",
"      Clarkson K, Rosenfeld B, Fair J, et al. Factor XI deficiency acquired by liver transplantation. Ann Intern Med 1991; 115:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/51\">",
"      Salomon O, Zivelin A, Livnat T, et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 2003; 101:4783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/52\">",
"      Zucker M, Zivelin A, Teitel J, Seligsohn U. Induction of an inhibitor antibody to factor XI in a patient with severe inherited factor XI deficiency by Rh immune globulin. Blood 2008; 111:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/53\">",
"      Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/54\">",
"      Rugeri L, Qu&eacute;lin F, Chatard B, et al. Thrombin generation in patients with factor XI deficiency and clinical bleeding risk. Haemophilia 2010; 16:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/55\">",
"      Setty S, Reddell A, England A, et al. The role of recombinant factor VIIa for obstetric block in women with severe factor XI deficiency. Haemophilia 2011; 17:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/56\">",
"      Riddell A, Abdul-Kadir R, Pollard D, et al. Monitoring low dose recombinant factor VIIa therapy in patients with severe factor XI deficiency undergoing surgery. Thromb Haemost 2011; 106:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/57\">",
"      Salomon O, Steinberg DM, Seligshon U. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia 2006; 12:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/58\">",
"      Bolton-Maggs PH, Young Wan-Yin B, McCraw AH, et al. Inheritance and bleeding in factor XI deficiency. Br J Haematol 1988; 69:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/59\">",
"      Kitchens CS. Factor XI: a review of its biochemistry and deficiency. Semin Thromb Hemost 1991; 17:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/60\">",
"      Kadir RA, Lee CA, Sabin CA, et al. Pregnancy in women with von Willebrand's disease or factor XI deficiency. Br J Obstet Gynaecol 1998; 105:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/61\">",
"      Salomon O, Steinberg DM, Tamarin I, et al. Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinolysis 2005; 16:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/62\">",
"      Chi C, Kulkarni A, Lee CA, Kadir RA. The obstetric experience of women with factor XI deficiency. Acta Obstet Gynecol Scand 2009; 88:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/63\">",
"      Myers B, Pavord S, Kean L, et al. Pregnancy outcome in Factor XI deficiency: incidence of miscarriage, antenatal and postnatal haemorrhage in 33 women with Factor XI deficiency. BJOG 2007; 114:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/64\">",
"      Ghosh N, Marotta PJ, McAlister VC. Correction of factor XI deficiency by liver transplantation. N Engl J Med 2005; 352:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/65\">",
"      Lee CA, Chi C, Pavord SR, et al. The obstetric and gynaecological management of women with inherited bleeding disorders--review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization. Haemophilia 2006; 12:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/66\">",
"      Berliner S, Horowitz I, Martinowitz U, et al. Dental surgery in patients with severe factor XI deficiency without plasma replacement. Blood Coagul Fibrinolysis 1992; 3:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/67\">",
"      O'connell NM. Factor XI deficiency. Semin Hematol 2004; 41:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/68\">",
"      Livnat T, Tamarin I, Mor Y, et al. Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. Thromb Haemost 2009; 102:487.",
"     </a>",
"    </li>",
"    <li>",
"     Arun B, Kessler C. Clinical Manifestations and Therapy of the Hemophilias. In: Hemostasis and Thrombosis, Basic Principles and Clinical Practice, 4th ed, Colman R, Hirsh J, Marder V, et al. (Eds), Lippincott Williams and Wilkins, Philadelphia 2001. p.822.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/70\">",
"      Santoro C, Goldberg I, Bridey F, et al. Successful hip arthroplasty in an adult male with severe factor XI deficiency using Hemoleven&reg;, a factor XI concentrate. Haemophilia 2011; 17:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/71\">",
"      Bolton-Maggs PH, Colvin BT, Satchi BT, et al. Thrombogenic potential of factor XI concentrate. Lancet 1994; 344:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/72\">",
"      Mannucci PM, Bauer KA, Santagostino E, et al. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood 1994; 84:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/73\">",
"      Richards EM, Makris MM, Cooper P, Preston FE. In vivo coagulation activation following infusion of highly purified factor XI concentrate. Br J Haematol 1997; 96:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/74\">",
"      Bauduer F, Bendriss P, Freyburger G, et al. Use of desmopressin for prophylaxis of surgical bleeding in factor XI-deficient patients. Acta Haematol 1998; 99:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/75\">",
"      Castaman G, Ruggeri M, Rodeghiero F. Clinical usefulness of desmopressin for prevention of surgical bleeding in patients with symptomatic heterozygous factor XI deficiency. Br J Haematol 1996; 94:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/76\">",
"      Franchini M, de Gironcoli M, Lippi G, et al. Prophylactic use of desmopressin in surgery of six patients with symptomatic heterozygous factor XI deficiency. Haematologica 2000; 85:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/77\">",
"      White B, Lawler P, Riddell A, et al. Response to desmopressin of factors XI, X and V in patients with factor VIII deficiency and von Willebrand disease. Br J Haematol 2004; 126:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/78\">",
"      Billon S, Le Niger C, Escoffre-Barbe M, et al. The use of recombinant factor VIIa (NovoSeven) in a patient with a factor XI deficiency and a circulating anticoagulant. Blood Coagul Fibrinolysis 2001; 12:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/79\">",
"      Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis 1990; 1:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/80\">",
"      Lawler P, White B, Pye S, et al. Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency. Haemophilia 2002; 8:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/81\">",
"      Salomon O, Zivelin A, Livnat T, Seligsohn U. Inhibitors to Factor XI in patients with severe Factor XI deficiency. Semin Hematol 2006; 43:S10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/82\">",
"      Schulman S, N&eacute;meth G. An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency. Haemophilia 2006; 12:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/83\">",
"      Brown SA. What dose of recombinant activated factor VII should be used in patients with factor XI deficiency? Haemophilia 2005; 11:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/84\">",
"      Meijers JC, Tekelenburg WL, Bouma BN, et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/85\">",
"      Cushman M, O'Meara ES, Folsom AR, Heckbert SR. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood 2009; 114:2878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/86\">",
"      Eichinger S, Sch&ouml;nauer V, Weltermann A, et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004; 103:3773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/87\">",
"      Yang DT, Flanders MM, Kim H, Rodgers GM. Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events. Am J Clin Pathol 2006; 126:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/88\">",
"      Salomon O, Steinberg DM, Koren-Morag N, et al. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111:4113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/14/37097/abstract/89\">",
"      Salomon O, Steinberg DM, Zucker M, et al. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost 2011; 105:269.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1333 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-41.78.124.10-0E38AEEEDF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_14_37097=[""].join("\n");
var outline_f36_14_37097=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10226536\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOLOGY OF FACTOR XI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Role in coagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Structure and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      FACTOR XI MUTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Combined coagulation deficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INHERITED FACTOR XI DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - General population",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Jewish populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ACQUIRED FACTOR XI DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25453942\">",
"      Decreased production or increased consumption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      FXI inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bleeding manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Menses and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      LABORATORY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10520694\">",
"      Making the diagnosis of FXI deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10520702\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10520752\">",
"      Labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10520743\">",
"      AVAILABLE TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Antifibrinolytic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      FXI replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Fresh-frozen plasma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - FXI concentrates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Desmopressin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Recombinant factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10520425\">",
"      POSSIBLE PROTECTIVE EFFECTS OF FACTOR XI DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10226536\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1333\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1333|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?31/46/32494\" title=\"algorithm 1\">",
"      Thrombin generation pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1333|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/45/43740\" title=\"table 1\">",
"      Causes PT and PTT abnormalities",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24650?source=related_link\">",
"      Acquired inhibitors of coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/62/39910?source=related_link\">",
"      Clinical manifestations and diagnosis of pulmonic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16730?source=related_link\">",
"      Rare (recessively inherited) coagulation disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_14_37098="Normal RA and PCW and LV pressures";
var content_f36_14_37098=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 622px\">",
"   <div class=\"ttl\">",
"    Normal RA, PCW, and LV pressures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 602px; height: 400px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Morton Kern.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_14_37098=[""].join("\n");
var outline_f36_14_37098=null;
var title_f36_14_37099="Nonabsorbable sutures";
var content_f36_14_37099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nonabsorbable sutures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Suture material",
"       </td>",
"       <td class=\"subtitle1\">",
"        Knot security",
"       </td>",
"       <td class=\"subtitle1\">",
"        Wound tensile strength",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tissue reactivity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Workability",
"       </td>",
"       <td class=\"subtitle1\">",
"        Anatomic site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nylon (Ethilon)",
"       </td>",
"       <td>",
"        Good",
"       </td>",
"       <td>",
"        Good",
"       </td>",
"       <td>",
"        Minimal",
"       </td>",
"       <td>",
"        Good",
"       </td>",
"       <td>",
"        Skin closure anywhere",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polybutester (Novafil)",
"       </td>",
"       <td>",
"        Good",
"       </td>",
"       <td>",
"        Good",
"       </td>",
"       <td>",
"        Minimal",
"       </td>",
"       <td>",
"        Good",
"       </td>",
"       <td>",
"        Skin closure anywhere",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polypropylene (Prolene)",
"       </td>",
"       <td>",
"        Least",
"       </td>",
"       <td>",
"        Best",
"       </td>",
"       <td>",
"        Least",
"       </td>",
"       <td>",
"        Fair",
"       </td>",
"       <td>",
"        Skin closure anywhere. Blue dyed suture useful in dark-skinned individuals.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Silk",
"       </td>",
"       <td>",
"        Best",
"       </td>",
"       <td>",
"        Least",
"       </td>",
"       <td>",
"        Most",
"       </td>",
"       <td>",
"        Best",
"       </td>",
"       <td>",
"        Rarely used",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Hollander JE, Singer AJ. Laceration management. Ann Emerg Med 1999; 34:356. Copyright &copy; 1999 The American College of Emergency Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_14_37099=[""].join("\n");
var outline_f36_14_37099=null;
var title_f36_14_37100="Glomerulotubular balance";
var content_f36_14_37100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F77558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F77558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Glomerulotubular balance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 243px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Glomerulotubular balance proximal tubule. Since fractional Na+ and water reabsorption remains constant, total or absolute proximal reabsorption in a nephron is directly proportional to the single nephron glomerular filtration rate (SNGFR). A similar relationship between absolute Na+ reabsorption and the amount of Na+ delivered to the segment is present in the loop of Henle and the distal tubule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Spitzer A, Brandis M, J Clin Invest 1974; 53:279.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_14_37100=[""].join("\n");
var outline_f36_14_37100=null;
var title_f36_14_37101="Plasma concentrations A";
var content_f36_14_37101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    Plasma glucose concentrations during the 180 min period after meal ingestion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 360px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data are means &plusmn;SE.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Vilsboll, T, Krarup, T, Deacon, C, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50:609. Copyright &copy; 2001 The American Diabetes Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_14_37101=[""].join("\n");
var outline_f36_14_37101=null;
var title_f36_14_37102="Trans dist phalanx fx";
var content_f36_14_37102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse distal phalanx fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 169px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse fractures are at greater risk of displacement. Widening of the fracture line (as seen here) may indicate entrapment of the nail bed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Henry M. Fractures and Dislocations of the Hand. In: Rockwood and Green's Fractures in Adults, 5th edition, Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_14_37102=[""].join("\n");
var outline_f36_14_37102=null;
var title_f36_14_37103="FTT components";
var content_f36_14_37103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Components of failure to thrive in elderly adults",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 440px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_14_37103=[""].join("\n");
var outline_f36_14_37103=null;
